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 1
1 Introduction 
 
The communication between different cells through defined signaling networks is crucial 
for the development from a single cell in the early embryo to the fully developed human 
being. The communication is either mediated through direct cell-cell interaction or by 
direct binding of secreted soluble factors to specific receptors at the plasma membrane. 
Among these factors are cytokines, hormones, neurotransmitters as well as growth factors. 
A variety of signal transduction pathways induced by many factors create a complex 
network. Perturbation of the network can cause pathological conditions, resulting in 
defective development of an organism, and following premature death or physiological 
disability and disease. 
Bone morphogenetic proteins (BMPs) are multifunctional growth factors which belong to 
the transformation growth factor β (TGF-β) superfamily. The aim of this thesis was to 
investigate the interaction of BMPs and its novel inhibitor - Chordin-like 2 (CHL2). 
Therefore, the function, signal transduction and regulation of BMPs will be described in 
the followings. 
 
1.1 BMPs and TGF-β superfamily proteins 
 
BMPs and other members of the TGF-β superfamily exist in vertebrate and invertebrate 
animals. BMPs were originally isolated by their ability to induce ectopic bone and 
cartilage formation in vivo (Urist, 1965), but it became rapidly evident that BMPs also act 
as multifunctional regulators in morphogenesis during development in animals (Graff, 
1997; Wozney, 1998). So far, at least 30 TGF-β like proteins have already been described 
(Hogan, 1996; Schmierer and Hill, 2007), including BMPs, TGF-βs, Growth and 
differentiation factors (GDFs), Activin β-chains, Nodal, and Anti-Mullerian hormone 
(AMH, also termed Mullerian inhibiting substance, MIS).  
Members of this family regulate a large variety of biologic responses in many different 
cells and tissues during early embryogenesis (De Robertis and Kuroda, 2004), and later in 
organogenesis (Hogan, 1996; Kingsley, 1994). During the postnatal life, BMPs and their 
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analogues are also essential for tissue repair and homeostasis (Reddi, 1998; Rosen and 
Thies, 1992) as well as for growth control (Massague et al., 2000).  
Furthermore, BMPs and other TGF-β like proteins play important roles after birth in 
pathophysiology of several diseases including osteoporosis (Medici et al., 2006; 
Turgeman et al., 2002; Wu et al., 2003), osteoarthritis (Blaney Davidson et al., 2007; 
Chen et al., 2004; Drissi et al., 2005), kidney diseases (Bottinger, 2007; Gagliardini and 
Benigni, 2007; Zhu et al., 2007), cerebrovascular diseases (Chang et al., 2003; Dabek et 
al., 2006; Florio et al., 2007) and cancer (Buck and Knabbe, 2006; Hahn and Akporiaye, 
2006; Sekimoto et al., 2007). 
 
1.2 Structure of BMPs  
 
The TGF-β superfamily proteins can be organised into subfamilies according to the 
similarities of their amino acid sequences (Figure 1.1) (Schmierer and Hill, 2007; Sebald 
et al., 2004). On a molecular level, the proteins of the TGF-β superfamily are very similar. 
The overall fold of the protein backbones is almost identical even though the similarity in 
amino acid sequences of TGF-β superfamily members is very low. A typical feature of all 
proteins is a small cystine-knot motif, which is formed by seven well-conserved cysteine 
residues in the carboxy-terminal domain of the proteins (McDonald and Hendrickson, 
1993). One of these cysteine residues is used for covalent interchain disulfide bridging, 
and the others are involved in an intramolecular ring formation, known as the cystine knot 
configuration. The cystine knot is a folding motif that forces exposure of hydrophobic 
residues to the aqueous surrounding, and prevents the molecule from assuming a globular 
protein structure. Instead, it drives the molecules to undergo dimerization, resulting in 
highly stable dimeric proteins with a butterfly-shape structure (Figure 1.2) (Scheufler et 
al., 1999; Sebald et al., 2004).  
The precursor dimers are secreted as propeptides, which are activated by protease 
cleavage, such as the furin-type serine endoprotease at an Arg-x-x-Arg recognition 
sequence. The monomer could be described as a left hand: the N-terminal end as the 
thumb; the two β-sheets (each two-stranded) as the two fingers; and the central α-helix as 
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the wrist (Figure 1.2, B). In the dimer, the wrist of one monomer fits into the concave side 
of the fingers of the other monomer. The topology of the dimer (shown in Figure 1.2, A 
for BMP-2) is highly conserved in the TGF-β superfamily. BMP-2 exhibits two different 
types of surface-epitopes to interact with the respective receptors, the wrist and the 
knuckle epitopes (Figure 1.2, A). 
Figure 1.1: Phylogenetic trees derived from protein alignments of ligands in the TGF-β
superfamily in human and Drosophila melanogaster. Human proteins are shown in black and
Drosophila melanogaster proteins are in grey (Schmierer and Hill, 2007). 
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1.3 Receptors of BMPs 
 
Members in the TGF-β superfamily signal into a cell by assembling type I and type II 
serine-threonine kinase receptors in the cell membrane. The activated type I receptors 
then phosphorylate the the cytoplasmtic Smads proteins (Derynck et al., 1998; Liu et al., 
1995). Up to now seven type I and five type II receptor chains have been identified in 
mammals (Figure 1.3) (Newfeld et al., 1999). 
The structures of type I and type II receptors are similar. They have a short extracellular 
ligand-binding domain with some conserved cysteine residues, a single transmembrane 
domain, and an intracellular domain containing a serine–threonine kinase motif. The type 
I receptors, but not type II receptors, contain upstream of the kinase domain a GS-box 
with a characteristic repetition of serines and glycines (SGSGSG). Upon ligand dimer 
binding, two type II receptors form a heterohexameric complex with two type I receptors. 
Subsequently the constitutive kinases of the type II receptors activate the type I receptors 
and initiates the signal transduction cascade by phosphorylating downstream nuclear 
factors, which then translocate to the nucleus to activate or inhibit transcription. Thus 
signal transduction for BMPs requires both type I and type II receptors. Type I receptors 
are activated by type II receptors, and signals are mediated through type I receptors 
(Ebara and Nakayama, 2002). 
Figure 1.2: Crystal structure (A) and secondary structure elements (B) of BMP-2. The 
wrist epitopes for type I and knuckle epitopes for type II receptor binding as well as the 
finger- and wrist-like parts of the hand-like monomer are labelled (Sebald et al. 2004). 
A                                       B 
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According to the crystal structure of the BMP2/BMPR-IAEC complex, one BMP binds 
two receptor ectodomains at the ‘wrist’ epitope of the BMP (Keller et al., 2004; Kirsch et 
al., 2000) (Figure 1.4, A). In the BMP-7/ActR-IIEC complex (Greenwald et al., 2003) 
and in the ActA/ActR-IIBEC complex (Thompson et al., 2003), the type II receptor 
binds to the ‘knuckle’ epitope formed by the backside of the finger regions of the 
ligand monomer (Figure1.4, B, C). The crystal structure of the ternary complexes of 
BMP-2/BMPR-IAECD/ActR-IIECD and BMP-2/BMPR-IAECD/ActR-IIBECD reveals that 
the fold and assembly of BMP-2 or BMP-7 in binary and ternary complexes with type I 
and type II receptors are very similar, the receptor ectodomains bind independently and 
have no direct contacts. The BMPs function as rigid scaffolds which hold the receptor 
ectodmains together for transactivation (Figure 1.4, D) (Allendorph et al., 2006; Weber et 
al., 2007).  
 
Figure 1.3: A, Sequence similarities of receptor ectodomains in the TGF-β superfamily (Sebald et 
al. 2004). B, Type I and Type II Serine/Threonine Kinase Receptors involved in the signaling 
pathway of TGF-β superfamily members and their ligands (Balemans and Van Hul, 2002). 
Serine/threonine kinase receptor Ligand 
Type I receptors  
ALK-1 BMPs 
ALK-2 or ActR-I BMPs, Activin 
ALK-3 or BMPR-IA BMPs 
ALK-4 or ActR-IB TGF-β, Activin 
ALK-5 or TGFR-I TGF-β, Activin 
ALK-6 or BMPR-IB BMPs, AMH 
ALK-7 ? 
  
Type II receptors   
Activin type II (ActR-II) Activin, BMPs 
Activin type IIB (ActR-IIB) Activin, BMPs 
TGF-type II receptor (TGFR-II) TGF-β 
BMP type II receptor (BMPR-II) BMPs 
Anti-mullerian hormone type II 
receptor (AMHR-II) 
AMH 
A                         B 
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1.4 Signal transduction pathways of BMPs 
 
BMP signals by at least two different intracellular pathways (Figure 1.5). The so called 
Smad-dependent pathway employs Smad proteins; one so called Smad-independent 
pathways include p38-MAPK and ERK pathway. 
 
Smad-dependent pathway 
At least eight Smads have been identified in mammals and two additional Smads, Smads 
9 and 10, in lower species. There are three classes of Smads: 1) receptor regulated Smads 
(R-Smads) that can be activated by the type I receptors, such as BMP activated Smad 
1/5/8, or TGF-β and Activin activated, Smad 2/3; 2) common TGF-β and BMP mediator 
Smads (Co-Smad), Smad 4, which oligomerizes with activated R-Smads; and 3) 
Figure 1.4: Crystal structure of BMPs or activin complexed with receptor ectodomains. A, BMP-2 
and the BMPR-IA ectodomain (Kirsch et al., 2000a and Keller et al., 2004). B, BMP-7 and the 
ActR-II ectodomain (Greenwald et al., 2003). C, Activin and the ActR-IIB ectodomain (Thompson et 
al., 2003). D, Ternary complex of BMP-2/BMPR-IA/ActR-IIB ectodomain (Weber at al., 2007). 
A B 
C D 
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inhibitory Smads (I-Smads), Smad 6 and 7, which get activated upon ligand stimulation. 
Smad6/7 exert a negative feedback effect by marking the receptors for degradation and by 
competing with R-Smads for receptor interaction (Canalis et al., 2003).  
Smad proteins have conserved N- and C-terminal regions, named the MH1 and MH2 
(MAD homology) domains, respectively. Both domains are bridged by a proline-rich 
linker region. The MH1 domain of R- and Co-Smads binds to DNA sequences and 
regulates nuclear import, and the MH2 domain binds to proteins, creating protein-protein 
interactions in gene transactivation. After ligand binding, the activated type I receptors 
phosphorylate intracellular Smad1/5/8 (BMPs as ligand) or Smad2/3 (TGF-β and Activin 
as ligand) on two serine residuces near the c-terminal. Upon phosphorylation, the Smads 
interact with the Co-Smad, Smad4, and form Smard1/5/8-Smad4 or Smard2/3-Smard4 
complex, which is translocated into the nucleus to regulate transcription (Liu et al., 1996; 
Figure 1.5: Cascade of BMP Smad signaling pathway. BMP dimers bind to serine/threonine 
kinase receptors type I and II. Upon ligand binding, type II receptors transphosphorylate type I 
receptors. The latter phosphorylate members of the Smad family of transcription factors. These 
Smads are subsequently translocated to the nucleus, where they activate transcription of target 
genes (Balemans and Van Hul, 2002).
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Macias-Silva et al., 1996). 
In the nucleus, Smads regulate transcription of target genes by binding to specific DNA 
sequences, or by interacting with some DNA-binding proteins. 1) Smad-binding DNA 
sequences. Smad3 and Smad4 directly bind to Smad-binding elements (SBEs; AGAC or 
GTCT sequence). Smad2 forms a complex with Smad3 and Smad4, and indirectly binds 
to SBEs. In contrast, Smad1/5/8 bind to the AGAC/GTCT sequence only weakly, and 
instead bind to the GCCGnCGC sequence of some target genes (Kim et al., 1997; 
Kusanagi et al., 2000). 2) Smad-interacting proteins. Some proteins, including 
transcription factors and transcriptional co-activators/co-repressors, interacting with 
R-Smads in the nucleus also play critical roles in mediating BMP-specific signals by 
regulating the transcription of target genes. Runx2, a member of transcription factors, can 
physically interact with R-Smads upon activation of BMP signaling, and co-operatively 
regulate the transcription of target genes, leading to osteoblast differentiation of 
mesenchymal progenitor cells (Ito and Miyazono, 2003; Miyazono et al., 2004; Zhang et 
al., 2000). Menin, another transcription factor, can physically interact with R-Smads and 
Runx2 in mesenchymal stem cells, and facilitates transcriptional activity induced by 
BR-Smads and Runx2 in the earlier stage (commitment phase) of osteoblast 
differentiation (Sowa et al., 2004). Furthermore some transcriptional co-activators (p300, 
CBP, GCN5 and P/CAF) and co-repressors (c-Ski and SnoN) physically interact with 
R-Smads upon ligand stimulation and regulate Smad-dependent transcription of target 
genes (Miyazono et al., 2005). 3) A number of direct BMP target genes have been 
identified, such as Xvent2 and Xvent2B, msx1, msx2, Id1, Id2, Id3, GATA2, Dlx5, Tob, 
and FGFR2 (Friedle and Knochel, 2002; Hollnagel et al., 1999; Hussein et al., 2003; 
Korchynskyi and ten Dijke, 2002; Ladher et al., 1996; Miyama et al., 1999; Peiffer et al., 
2005; Rastegar et al., 1999; von Bubnoff et al., 2005; Yoshida et al., 2000). 
 
Smad-independent pathway 
In addition to Smad activation, BMPs and TGF-β can activate Smad-independent 
pathways. The small GTPase and the mitogen-activated protein kinases (MAPKs) ERKs, 
p38 and c-Jun N-terminal kinases (JNKs) are the main signaling proteins in 
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Smad-independent pathways (Moustakas and Heldin, 2005). The p38 is essential in 
BMP-2 induced up-regulation of type I collagen, osteocalcin, and alkaline phosphatase 
activity; p38 and ERK mediate BMP2 stimulation of fibronectin and osteopontin 
(Attisano and Wrana, 2002; Lai and Cheng, 2002). 
 
1.5 Modulation of BMP signaling 
 
BMP signaling is delicately regulated at multiple levels: intracellularly, at the cell 
membrane site, and extracellularly (Figure 1.6). 
 
Figure 1.6: Three levels of modulation of BMP signaling. (1) I-Smads and Smurfs regulate 
intracellular signaling by preventing further Smad signaling and consequent activation of gene 
transcription, (2) Pseudoreceptor BAMBI/Nma modulates BMP signaling at the membrane 
site by binding to BMP type II receptors, and (3) Extracellular antagonists modulate binding of 
BMP dimers to the BMP type I and type II receptors (Balemans and Van Hul, 2002). 
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1.5.1 Intracellular modulation 
 
The first level of regulation resides within the cell cytoplasm, where inhibitory Smads, 
Smurfs and some other intracellular proteins act as modulators.  
 
Inhibitory Smads 
Smads have conserved N- and C-terminal domains, termed MH1 and MH2 domains 
respectively. Inhibitory Smads (I-Smads), Smad6 and Smad7, have MH2 domains, but 
their N-terminal sequences are highly divergent from the MH1 domains of other Smads 
(Miyazono, 2000). Smad6 preferentially inhibits BMP signaling, whereas Smad7 inhibits 
both TGF-b/Activin and BMP signaling. I-Smads antagonize the TGF-β signaling 
pathway either by interacting with phosphorylated type I receptors and thereby preventing 
the activation of R-Smads, or through competition with Co-Smads for the formation of 
the R-Smad/Co-Smad complexes (Itoh et al., 2001). The expression of I-Smads also can 
be regulated by multiple stimuli, including epidermal growth factor (EGF) and various 
TGF-β family members, such as TGF-β1, Activin, and BMP-7 (Miyazono et al., 2005). 
. 
Smurfs 
Smads can be regulated at the level of degradation which is controlled by the 
ubiquitin-proteasome system. Ubiquitin is a highly conserved protein that covalently 
binds and recruits target proteins for their degradation by the proteasome. It regulates in 
particular the level of nuclear factors and thereby modifies transcription (Conaway et al., 
2002). Two closely related Smurfs (Smad ubiquitination regulatory factors), Smurf1 and 
Smurf2, have been identified in vertebrates and are mediators of the final step in 
ubiquitination of target proteins (Zhu et al., 1999). Smurfs, containing HECT catalytic 
domains characteristic of E3-ubiquitin ligases, induce export of I-Smads from the nucleus 
to the cytoplasm and interact with activated type I receptors through I-Smads. In fact, 
interaction of I-Smads with type I receptors is enhanced by Smurfs, resulting in 
suppression of TGF-β signaling (Ebisawa et al., 2001; Kavsak et al., 2000). Moreover, 
Smurfs induce ubiquitin-dependent degradation of the type I receptors and R-Smad, 
leading to down-regulation of the number of receptors and R-Smad (Lin et al., 2000; 
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Miyazono et al., 2005; Zhang et al., 2001).  
 
Ski and SnoN 
Ski is a nuclear oncoprotein homologous to the transforming protein (v-Ski) of the avian 
Sloan-Kettering retrovirus, which is an important TGF-β negative regulator. SnoN is 
structurally closely related to Ski. Ski interacts with the Smad 2/3 and Smad 4, interfering 
with the formation of functional Smad complex (Luo, 2003). Ski inhibits TGF-β and 
BMP signaling through several mechanisms: 1) stabilization of pre-formed Smad 
complexes on DNA preventing the access of newly activated Smads to the Smad binding 
element; 2) interference of Smad binding to transcriptional activators; and 3) recruitment 
of nuclear co-repressors and the histone deacetylase complex (HDAC) (Suzuki et al., 
2004). 
 
Tob 
The transducer of ErbB-2 (tob) gene is a member of the PC3/BTG/Tob family of genes, 
which are involved in cell replication and differentiation. Tob decreases BMP signaling 
by binding Smad 1/5/8 and by interacting with BMP type I receptors associated with 
I-Smads. The tob gene is expressed in osteoblastic cells and its transcript levels are 
up-regulated by BMP-2 (Gazzerro and Canalis, 2006; Yoshida et al., 2003). 
 
1.5.2 Membrane Receptor Modulation 
 
The transmembrane protein BAMBI (BMPs and Activin membrane bound inhibitor), 
playing a role in attenuating BMP signaling, was identified in Xenopus. BAMBI encodes 
a TGF-β pseudoreceptor, which is a putative transmembrane protein with an extracellular 
domain similar to that of type I TGF-β and BMP receptors, but lacks intracellular 
serine/threonine kinase domain. BAMBI interferes with BMPs, Activin, and TGF-β 
signaling by stably associating with type IA and IB BMP receptors, thus preventing the 
formation of active receptor complexes. BAMBI is co-expressed with BMP-4 during 
embryogenesis and plays a critical role in defining BMPs action in embryo dorsalization 
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(Onichtchouk et al., 1999). BAMBI is expressed in terminally differentiated osteoblasts 
and its transcripts are up-regulated by BMPs, TGF-β and Wnt (Kalajzic et al., 2005). 
 
1.5.3 Extracellular Modulation 
 
In the extracellular space, there is another control system to modulate BMPs action 
through a group of secreted polypeptides. These extracellular BMP antagonists prevent 
BMP signaling by binding BMPs, therefore precluding their binding to specific cell 
surface receptors. Extracellular BMP antagonists include noggin, Dan family members, 
twisted gastrulation, follistatin and Chordin family members. 
 
Noggin 
Noggin is secreted as a homodimeric glycosylated protein. The primary structure of 
noggin consists of an acidic aminoterminal region and a cysteine-rich carboxyterminal 
region containing a cystine knot. Noggin binds to BMP-2/4/5/6/7, GDF-5/6 with various 
degrees of affinity, but not to other members of the TGF-β family (Gazzerro and Canalis, 
2006). The crystal structure of the antagonist Noggin binding to BMP-7 show that Noggin 
inhibits BMP signalling by blocking the binding epitopes for both type I and type II 
receptors (Groppe et al., 2003). 
Noggin was first isolated from X. laevis based upon its ability to rescue dorsal 
development in embryos ventralized by UV treatment (Smith and Harland, 1992) and is 
expressed during early stages of gastrulation in the Spemann organizer (McMahon et al., 
1998). In the zebrafish embryo, three noggin orthologues have been isolated, noggin1, 
noggin2, and noggin3. Noggin1 is expressed in the organizing center of the zebrafish, and 
noggin2 transcripts first appear at the end of gastrulation. Both genes are expressed 
during somitogenesis and during formation of the nervous system. Noggin1 and noggin2 
overexpression strongly dorsalizes the embryo, and play a role in dorsoventral patterning 
of the zebrafish (Bauer et al., 1998). During the early stages of mouse embryonic 
development, noggin is expressed in the node. Later on in mouse embryonic development, 
noggin expression is seen in the notochord, the roof of the neural tube, the dorsal aspect 
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of the somites, and the limbs. Expression of noggin in these later sites has profound 
effects on development (Bachiller et al., 2000). Noggin’s function is essential in skeletal 
and joint development in mice: homozygous mice for noggin-null mutant had excess 
cartilage and failed to initiate joint formation (Brunet et al., 1998). The importance of the 
noggin gene was confirmed by human studies, which demonstrated that different 
heterozygous missense mutations of noggin coding sequence lead to proximal 
symphalangism and multiple synostosis syndromes (Gong et al., 1999; Marcelino et al., 
2001). The gene substitutions identified in these patients seem to affect noggin protein 
folding and stability rather than BMP binding affinity (Groppe et al., 2003). 
 
Dan Family 
Differential screening-selected gene aberrative in Neuroblastoma (Dan) is a member of 
Dan family of secreted glycoproteins capable of binding BMPs. At least nine members of 
the Dan family have been described: Gremlin, Dan, uterine sensitization associated gene 
(USAG-1), Cerberus, Caronte, Coco, protein related to Dan, Cerberus (PRDC) and Dante. 
Protein sequence alignments reveal that these proteins share a common carboxyterminal 
cysteine-rich domain consisting of nine cysteines. Outside the cysteine-rich domain, they 
have limited homology. Most of the Dan family members can bind to BMP-2/4/5/6/7 with 
various degrees of affinity and have the capability of inhibiting BMP signaling. Most of 
the members of the Dan family are expressed primarily during embryonic development 
and play a minor role in skeletogenesis. Gremlin, however is an important regulator of 
BMP activity in the adult skeleton (Gazzerro and Canalis, 2006). 
 
Twisted gastrulation 
Twisted gastrulation (Tsg) is a secreted glycoprotein which was originally identified in 
Drosophila and is required for the proper establishment of the dorso-ventral axis (Mason 
et al., 1994). Tsg is expressed during embryonic development and in a wide variety of 
adult tissues (Oelgeschlager et al., 2003). 
Tsg has two evolutionary conserved cysteine-rich domains. The amino-terminal 
cysteine-rich domain has some analogies with the cysteine-rich domains of Chordin and 
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is responsible for a direct interaction between Tsg and BMP-2/-4. The carboxy-terminal 
region does not have significant homology to known protein motifs, and interacts with 
Chordin. Tsg display both BMP antagonist and agonist functions. As a BMP antagonist, 
Tsg binds directly with BMP-2/4 or generates a trimolecular complex with a 
BMP-Chordin preformed complex, which is more efficient than its individual components 
in inhibiting BMP signaling (Chang et al., 2001; Ross et al., 2001; Scott et al., 2001; 
Wills et al., 2006). As a BMP agonist, Tsg can enhance Chordin cleavage by 
tolloid/xolloid, and prevent the residual anti-BMP activity of Chordin proteolytic products 
(Larrain et al., 2001; Oelgeschlager et al., 2000). The relative levels of Tsg, Chordin, and 
tolloid/xolloid appear to dictate whether Tsg inhibits or enhances BMP actions in a 
specific cell environment. 
 
Follistatin 
The follistatin protein has been isolated on the basis of its involvement during the 
reproductive cycle and is expressed in a wide range of embryonic and adult tissues, 
including brain, testis, ovary, bone marrow, placenta, and the anterior pituitary (Patel, 
1998). Follistatin was initially identified as an Activin-binding protein that prevents 
Activin from binding to its receptor (Hemmati-Brivanlou et al., 1994), but it also can bind 
BMP-2, -4 and -7 (Iemura et al., 1998; Yamashita et al., 1995).  
The three dimensional structure of follistatin-Activin complex is known. In 
follistatin-Activin complex, two follistatin monomers surround the dimeric ligand and 
bury the binding sites for type I and type II receptors (Harrington et al., 2006; Thompson 
et al., 2005). Mutational analysis revealed that only residues at the type II 
receptor-binding surface of Activin are critical for high-affinity follistatin binding and the 
interaction surface of Activin for type II receptors and follistatin are overlapping but not 
identical (Harrison et al., 2006). 
 
Chordin Family 
This thesis focuses on the Chordin family member Chordin-like 2. Therefore the 
introductions of Chordin family and Chordin-like 2 are listed under separate subtitles 
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below (see 1.5.4 and 1.6). 
 
1.5.4 Chordin family  
 
VWC-containing proteins 
As described above, the activity of BMPs is modulated by a large number of extracellular 
regulator proteins. These proteins include Chordin-like proteins which contain Von 
Willebrandt factor type C (VWC) domains. VWC domain, also called cysteine-rich 
domain (CR), typically contains less than 100 residues and have in common a conserved 
CXXCXC motif in the middle and CCXXC motif in the carboxyterminus. Otherwise, the 
sequences of the VWC domain are highly diverse. The VWC exists in about 500 
extracellular proteins from drosophila to human (82 proteins in h. sapiens and 85 proteins 
in m. musculus, available at www.sanger.ac.uk/cgi-bin/Pfam/getacc?PF00093). The 
cellular role of most VWCs is as yet unknown. For some VWCs existing in proteins of 
the Chordin family, however, it has been established that they bind BMPs and thereby 
modulate their activity during development. These proteins play important roles in 
development and diseases. The VWC-containing proteins, no matter if they inhibit or 
promote BMP activity, all bind BMPs via their VWC domains. These proteins include 
Chordin, Kielin, Crossveinless-2, members of CCN family, Chordin-like 1, Chordin-like 
2 and others (Garcia Abreu et al., 2002). 
 
Chordin is a typical VWC-containing protein and its VWC domains are shown in Figure 
1.7 (Garcia Abreu et al., 2002; Zhang et al., 2007) and Figure 1.8. Chordin has four VWC 
domains of about 70 amino acids each. These domains, particularly VWC1 and VWC3, 
determine the function of Chordin and its ability to bind BMPs. Chordin binds 
specifically BMP-2/4/7 and prevents their interaction with BMP receptors (Larrain et al., 
2000; Piccolo et al., 1996).  
Chordin was initially identified in the Xenopus Spemann Organizer for its ability to 
antagonize BMP action and is the homolog of Short Gastrulation (Sog) in Drosophila. 
Chordin is highly expressed in undifferentiated chondrocytes where it acts as an inhibitor 
of cell differentiation. The levels of Chordin decline in mature cartilage tissue (Gazzerro 
and Canalis, 2006). Chordin deficient mice demonstrate early lethality and a ventralized 
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gastrulation phenotype (Bachiller et al., 2000). Surviving mutant embryos die perinatally, 
and they display an extensive array of malformations in pharyngeal and cardiovascular 
organization that encompass most features of DiGeorge and Velo-Cardio-Facial 
syndromes in humans (Bachiller et al., 2003). 
 
 
Chordin is regulated by interactions with other secreted proteins of the extracellular 
matrix, such as the zinc metalloprotease Tolloid/Xolloid, which cleaves Chordin to 
inactivate its biological activity and to release free BMPs to the extracellular space 
(Piccolo et al., 1997). Tolloid/Xolloid is expressed in articular and growth plate 
chondrocytes and in osteoblastic cells (Reynolds et al., 2000). The proteolytic activity of 
Tolloid/Xolloid is specific for Chordin and does not modify the action of other BMP 
Figure 1.7: Diagram showing the position of the four VWCs (VWC1–4) of Chordin (A) and 
sequence alignment showing amino acid similarities between VWC-1, VWC-2, VWC-3 and VWC-4 
of human Chordin (B). Ten cysteines highlighted in black are conserved and present in a typical 
spacing found in all vertebrate Chordins, in Drosophila Sog and in many VWC-containing proteins. 
A glycine (G), tryptophan (W) and the CXXCXC and CCXXC motifs are highly conserved among 
VWCs. (Garcia Abreu et al., 2002) 
B 
A 
Figure 1.8: Domain composition of VWC containing proteins. hCHL2, human Chordin-like 2; 
hCHL1, human Chordin-like 1; CV2, crossveinless-2 (Chicken); Keilin (mouse); Chordin (human). 
VWC, Von Willebrandt factor type C domain; VWD, Von Willebrandt factor type D domain; TIL, 
trypsin Inhibitor-like cysteine-rich domain. 
429                                         hCHL2
450                                      hCHL1
678                       CV2
1254       Keilin
955  Chordin
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antagonists. Tolloid/Xolloid action can be inhibited by secreted Frizzled-related protein 
(sFRP) -Sizzled. The Xolloid-related proteinase has similar affinities for its endogenous 
substrate Chordin and for its competitive inhibitor Sizzled. Therefore Sizzled can 
competitively inhibit Chordin binding to the active site of the Xolloid-related 
metalloprotease, and thus stabilize Chordin levels and regulate BMP signaling in the 
embryo (Lee et al., 2006). 
Chordin cleavage by Xolloid is modulated by Tsg. Tsg has two distinct and sequential 
activities on BMP signaling. First, Tsg makes Chordin a better BMP antagonist by 
forming a ternary complex that prevents binding of BMP to its cognate receptor. Second, 
after full-length Chordin is cleaved by Xolloid, Tsg competes the residual anti-BMP 
activity of Chordin fragments and facilitates their degradation, providing a permissive 
Figure 1.9: Model for a biochemical pathway that regulates BMP signaling in the extracellular 
space. This model explains why Tsg has the dual ability to increase BMP antagonism by 
full-length Chordin and to promote BMP signaling after Xolloid cleavage. Tsg-BMP complexes 
can be bound by full-length Chordin to form a ternary complex that is a potent BMP antagonist. 
Xolloid cleaves Chordin releasing Tsg-BMP binary complexes and Chordin fragments. In the 
presence of full-length Chordin, the binary complex will re-bind to Chordin, reforming the ternary 
complex. After full-length Chordin is cleaved by Xolloid, however, Tsg is able to dislodge BMP 
from Chordin and to destabilize the Chordin proteolytic products, displacing the equilibrium. 
(Modification from Larrain J et al. 2001). 
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signal that promotes BMP binding to its cognate receptor. Therefore Tsg has the dual 
ability to increase BMP antagonism by full-length Chordin and to promote BMP 
signaling after Xolloid cleavage (Figure 1.9)(Larrain et al., 2001). 
In addition, another model for Chordin (Sog) regulating mechanism in which Chorin/Tsg 
functions as BMP transporter has been described in drosophila (Shimmi et al., 2005). 
Decapentaplegic (Dpp) and Screw (Scw), the homologues of vertebrate BMP2/4 and 
BMP6/7, are required for patterning the dorsal surface of the drosophila blastoderm 
embryo. The ventral/dorsal sides of drosophila are reverse to those in vertebrate. In 
drosophila, Thick veins (Tkv) and Saxophone (Sax) are type I receptors that act 
synergistically to transduce the Dpp and Scw signals, respectively (Haerry et al., 1998; 
Neul and Ferguson, 1998; Nguyen et al., 1998). Signaling of Dpp/Scw is regulated at the 
extracellular level by the BMP binding proteins Sog and Tsg. Homodimers and 
heterodimers of Dpp and Scw are produced throughout the dorsal domain. Sog is 
expressed and secreted in the ventral lateral region and diffuses toward the dorsal side. 
Dpp and Scw homodimers do not bind to Sog and Tsg with high affinity and produce 
only low-level signals that can activate targets. In contrast, Dpp/Scw heterodimers bind 
with high affinity to Sog and Tsg. Net flux of the complex toward the dorsal midline leads 
to an increase in the heterodimer concentration at the midline. Tolloid processes Sog at 
the midline to release the ligand, which then binds to a receptor complex containing both 
Sax and Tkv. This complex produces a synergistic high signal that activates high-level 
response genes and leads to specification of the amnioserosa, a typical phenotype of 
BMP-enhancing (pro-BMP) activity of Sog/Tsg in Drosophila. So the heterodimer of 
Dpp and Scw, but not the Dpp homodmer, is the primary transported ligand and the 
heterodimer signals synergistically through the two type I BMP receptors Tkv and Sax. 
The Dpp/Scw heterodimer is a preferred binding partner for Sog/Tsg and preferentially 
stimulates Sog cleavage by Tolloid (Figure 1.10). 
 
Kielin is a kind of Chordin-like secreted protein of Drosophila which contains 27 VWC 
domains. Kielin also contains an aminoterminal TSP domain and a carboxylterminal Von 
Willebrandt factor type D (VWD) domain (Matsui et al., 2000). Mouse 
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Kielin/Chordin-like protein (KCP), the homology of Drosophila Kielin which contains 17 
VWC domains, could attenuate the pathology of renal fibrotic disease by enhancing BMP 
signaling while suppressing TGF-β activation (Lin et al., 2005; Lin et al., 2006). It binds 
BMP7 and enhances the BMP7 binding to type I receptor. However, which domain of 
Kielin is involved in BMP binding is unknown. 
 
Crossveinless-2 (CV2) is a secreted protein that contains five VWC domains and a VWD 
domain at the carboxyterminus (Figure1.8; Conley et al., 2000). CV2 plays essential 
pro-BMP roles in mouse organogenesis (Ikeya et al., 2006) and zebra fish gastrulation 
Figure 1.10: Model for patterning dorsal tissues in the Drosophila embryo. Homodimers and 
heterodimers of Dpp and Scw are produced throughout the dorsal domain. Sog is expressed and 
secreted in the ventral lateral region and diffuses toward the dorsal side. Dpp and Scw homodimers 
do not bind to Sog and Tsg with high affinity. As a result, they are free to bind with receptors, but 
they produce only low-level signals that can activate targets. In contrast, Dpp/Scw heterodimers
bind with high affinity to Sog and Tsg. Net flux of the complex toward the dorsal midline leads to 
an increase in the heterodimer concentration at the midline. Tolloid (Tld) processes Sog at the 
midline to release the ligand, which then binds to a receptor complex containing both Sax and Tkv. 
This complex produces a synergistic high signal that activates high-level response genes and leads 
to specification of the amnioserosa (Shimmi et al., 2005).
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(Rentzsch et al., 2006). On the other hand, CV2 can also inhibit BMP signaling in certain 
context, especially in cell culture experiments (Binnerts et al., 2004). CV2 binds to 
BMP-2 via its VWC1 domain with high affinity and CV2-VWC1 domain governs all the 
binding affinity of CV2 to BMP (Zhang et al., 2007). Similar to full-length CV2, 
CV2-VWC1 could simultaneously block the binding of BMP-2 to both type I and type II 
receptors. 
 
Chordin-like 1 (CHL1) contains three VWC domains (Nakayama et al., 2001). It is also 
called neuralin-1 (mouse) (Coffinier et al., 2001) or ventroptin (chick retina) (Sakuta et al., 
2001). It antagonizes BMP-4,-5 and -6 and weakly interacts with TGF-β1 and -β2 in vitro 
(Nakayama et al., 2001; Sakuta et al., 2001). CHL1 interacts directly with BMPs in a 
competitive manner to prevent binding of BMPs to the type I BMP receptor ectodomain 
(Nakayama et al., 2001). 
On mouse embryos CHL1 expression starts at neural plate stage and extends to the entire 
neural plate at late headfold stage. The latter neural expression becomes restricted to 
discrete regions of the forebrain and midbrain, as well as in the closing posterior neural 
folds. Starting at much later mouse embryos, CHL1 expression is observed in a 
population of neural crest cells that migrate from the hindbrain and colonize the branchial 
arches. In addition, the dorsal root ganglia and other neural crest derivatives are positive 
for CHL1 expression. During organogenesis, CHL1 expression in the nervous system is 
observed in dorsal root ganglia and in superficial layers of the CNS (Coffinier et al., 
2001). In the adult brain, CHL1 (also called Neurogenesin-1) mRNA was intensely 
expressed in the hippocampus and moderately around the lateral ventricle. 
Immunohistochemistry revealed that astrocytes in the hippocampal dentate gyrus and the 
dentate granule cells adjacent to neural stem cells abundantly secreted CHL1. These 
results indicate that CHL1 also participates in adult hippocampal neurogenesis and 
induces neuronal differentiation in the adult brain (Ueki et al., 2003). Furthermore, high 
expression levels are seen in the developing skeletal structures, including limb bones, 
clavicles, calvaria, vertebra, and ribs. In the adult mouse, CHL1 is expressed in lung, 
kidney, and testis. Expression of CHL1 in nonskeletal mesenchymal cells has been 
demonstrated in many adult connective tissue cell types (Nakayama et al., 2001). CHL1 
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may function as a modulator of the BMP signaling in the neural plate and in bone 
formation, as well as in other processes. 
 
1.6 Chordin-like 2 
 
1.6.1 Structure of CHL2 protein 
 
 
Chordin-like 2 (CHL2) is a novel Chordin-like protein, and structurally most homologous 
to CHL1 and Chordin. CHL2 contains a signal peptide and three VWC domains. Mouse 
CHL2 (mCHL2) and human CHL2 (hCHL2) contain 426 and 429 amino acids 
respectively. hCHL2 has 73% amino acids homology to mCHL2 (Nakayama et al., 2004).  
Figure 1.11 shows the sequence alignment of the mouse Chordin, CHL1 and CHL2 
proteins and their VWC domains, indicating their high similarity. Between CHL1 and 
Figure 1.11: A, Schematic representation of chordin, CHL1 and CHL2. SP: signal peptide. The 
VWC1 and VWC3 regions in CHL1 and CHL2 (black boxes) are most homologous to VWC3 of 
chordin (in black). The chordin VWC1 (in gray) and VWC3 possess the BMP binding capability 
(Larrain et al., 2000). Putative BMP1/Tolloid cleavage sites are indicated with an asterisk, while 
actual Tolloid cleavage sites (Scott et al., 1999) are shown by vertical arrows. B, Amino acid 
sequence alignment showing sequence similarities between VWC1 or VWC3 of mouse CHL1 and 
CHL2, and VWC3 of mouse chordin. Ten conserved cysteines (highlighted in black) are found in 
the spacing typical of vertebrate chordins. Other conserved amino acids are highlighted in gray 
(Nakayama et al., 2004). The CXXCXC and CCXXC motifs are highly conserved among VWCs. 
A 
B 
CXXCXC                          CCXXC 
mCHL1 VWC1 
mCHL2 VWC1 
mChordin VWC3
 
 
mCHL1 VWC3 
mCHL2 VWC3 
mChordin VWC3
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CHL2, the similarity is further indicated in their length and amino acid sequence, the 
number and location of the VWC domains. The homology between CHL1 and CHL2 
proteins is confined primarily to the VWC domains. A higher level of conservation is 
observed within each of the VWC domains, and highest is within VWC3 repeats 
(Nakayama et al., 2004). 
 
1.6.2 Structure of CHL2 gene   
 
 
The observable similarity between CHL1 and CHL2 also extends to the structure of their 
respective genes, in both the human and mouse genomes, including the size of their exons 
A 
mCHL2-VWC1 
 
 
mCHL2-VWC2 
 
 
mCHL2-VWC3 
 
｜               exon2                ｜｜               exon3           ｜
.....ARSRSGKVCLFGEKIYTPGQSWHPYLEPQGTI..YCVRCTCSENGHVNCYRLRCPPLH.CSQPVMEPQQCCPRCVD
 
｜                    exon4                     ｜｜              exon5             ｜
PHVPSGLRVPLKSCQLNETTYQHGEIFSAQELFPARLSNQCVLCSCIE.GHTYCGLMTCPEPS.CPTTLPLPDSCCQTCKD
 
｜                             exon8                               ｜
.....LKEKHKKACTHNGKTYSHGEVWHPTVLSFGPMP..CILCTCID.GYQDCHRVTCPTQYPCSQPKKVAGKCCKICPE
 
｜                   SD1                 ｜          SD2          ｜
B 
Figure 1.12: A, Schematic representation of the human and mouse CHL2 and CHL genes showing 
the intron– exon genomic organization of the genes. Exons are depicted as boxes, and their size is 
given in base pair. Introns, not drawn to scale, are shown as thin lines. Coding and untranslated 
sequences are depicted in gray and white, respectively. Sequences encoding for the signal peptide 
(SP) and the VWC domains are indicated on top. Note that VWC1 and VWC2 are each encoded by 
two exons, while VWC3 is encoded by a single exon (Oren et al., 2004). B, Sequence alignment of 
VWC domains of mouse CHL2 (Multalin) showing the encoding of sub-domains of VWCs by 
different exon. The exons are indicated on top of the sequence. Residues are coloured according to 
conservation (hydrophobic: green; cysteine: yellow; positive charged: red; negative charged: purple; 
uncharged hydrophilic: blue. SD1 and SD2, sub-domains 1 and 2 of mCHL2-VWCs. 
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and the peculiar spacing of the VWC domains. In the human and mouse genomes, CHL2 
genes are composed of 11 exons that span a region of about 35 and 28 kb respectively. The 
structures of the human and mouse CHL2 genes (Figure 1.12, A) are very similar, in 
particular regarding the exon–intron boundaries, size of exons, and spacing of VWC 
domains within the exons. Two VWC domains are encoded each by two exons: exons 2 and 
3 encode for VWC1; exons 4 and 5 encode for VWC2. VWC3 is encoded only by exon 8 
(Oren et al., 2004). The NMR structure of the Col IIA VWC domain shows that each 
VWC domain contains two sub-domains (SD1 and SD2) (O'Leary et al., 2004). For the 
VWC1 of mCHL2, exon 2 encodes SD1 and exon 3 encodes SD2. Exons 4 and 5 encode 
SD1 and SD2 of mCHL2-VWC2 respectively. However, exon 8 encode two sub-domains 
of mCHL2-VWC3 (Figure 1.12, B). 
 
1.6.3 Normal expression of CHL2 
 
Skeletal Expression 
Northern blot analysis revealed little mCHL2 mRNA in the mouse embryo, in contrast to 
the abundant expression of mouse Chordin and mouse CHL1. In mouse embryos, mCHL2 
mRNA showed expression restricted to the surface chondrocytes of developing joint 
cartilage. In the adult mouse, mCHL2 was weakly expressed in cartilage of the femoral 
head, patella, articular facets of vertebrae and the annulus fibrosus of intervertebral discs. 
In general, mCHL2 expression in adult cartilage was weaker than that of embryonic 
cartilage. mCHL2 in normal cartilage was confined to articular chondrocytes, especially 
in the superficial zone. mCHL2 also showed low to moderate expression in sternal 
cartilage during embryogenesis and in joint cartilages of adult paws. But mCHL2 
transcripts were never detected in growth plate cartilage or bone during development or 
adulthood. Thus, among skeletal compartments, mCHL2 seems to be expressed 
preferentially in the superficial zone chondrocytes of developing articular cartilage 
(Nakayama et al., 2004). 
 
Non-Skeletal Expression 
In mouse tissues, mCHL2 mRNA was shown to be expressed in the connective tissue of 
reproductive organs such as ligaments of the ovary and oviduct in females, and of testis, 
epididymis and certain male accessory sex glands in males. mCHL2 mRNA was also 
present in maternally derived placental tissues and uterine myometrium. Otherwise on the 
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mouse adult tissue blot, a faint mCHL2 transcript was detected in liver, kidney, skeletal 
muscle and testis extracts (Nakayama et al., 2004). 
Northern blot analysis revealed hCHL2 transcript, which was highly expressed in uterus 
and was also detected in a variety of adult human tissues including colon, bladder, heart, 
stomach, prostate, ovary and testis (Nakayama et al., 2004; Oren et al., 2004). An analysis 
of fetal human tissues revealed expression of hCHL2 transcript in fetal liver. The 
immunohistochemical analysis of human tissues indicated expression of hCHL2 protein 
primarily in the secretory epithelial cells of uterine endometrium, fallopian tubes, 
endocervical glands, bladder, prostate, the transitional epithelium of the urinary bladder, 
as well as in bone osteoblasts (Oren et al., 2004). 
 
1.6.4 CHL2 mRNA expression in diseased cartilage 
 
In degenerating cartilage specimens from knees of adult humans, CHL2 mRNA was 
determined to be weakly expressed in human rheumatism (RA) patients, but expressed 
strongly in human osteoarthritis (OA) patients. Normally CHL2 is not relevant to normal 
pathways of chondrocyte proliferation and maturation. However, the upregulation of 
CHL2 transcripts specifically in middle zone cartilage of adult joints with OA revealed 
that CHL2 maybe has a role in cartilage repair by delaying and/or reducing the degree of 
chondrocyte hypertrophy, thereby amending cartilage degeneration. Thus CHL2 might 
negatively regulate cartilage formation/ regeneration in diseased joints (Nakayama et al., 
2004). However, Aigner (Aigner, 2006) argued that an upregulation of CHL2 in 
osteoarthritic cartilage was not supported by two experimental evidences. First, he 
pointed out that upregulation of BMP-inhibitory activity in osteoarthritic cartilage did not 
agree with some of the published data, which have shown that an overall upregulation of 
anabolic activity occurs in osteoarthritic chondrocytes (Aigner et al., 1992; Lippiello et al., 
1977), but not a downregulation. Second he argued that Nakayama (Nakayama et al., 
2004) took osteophytic cartilage as osteoarthritic degenerated cartilage. Osteophyte 
tissues derive from mesenchymal precursor cells which become active matrix-producing 
chondrocytes after being in a chondroprogenitor cell state. Finally, some of the 
chondrocytes become hypertrophic. Osteophyte growth essentially re-capitulates 
chondroneogenesis in fetal development. Therefore, osteophytic chondrocytes resemble 
the fetal chondrocytes in many respects. Thus, in his opinion, Nakayama observed CHL2 
being strongly expressed just in osteophytic chondrocytes, but not the chondrocytes of 
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osteoarthritic degenerated cartilage. 
 
1.6.5 Interaction of CHL2 and BMPs 
 
Nakayama et al. demonstrated that CHL2 bound directly to BMP-4 and prevented BMP-4 
interacting with its BMPR-IB receptor. In cell-based assay CHL2 inhibited BMP-2/4/6/7 
induced alkaline phosphatase (ALP) activity. The inhibitory potency is similar to noggin 
and stronger than that of Chordin (Nakayama et al., 2004).  
 
1.7 Aims of the thesis work 
 
The functions of VWC-containing proteins in development and diseases have been 
studied extensively. However, the structural basis of BMP/VWC-containing protein 
interaction is still poorly understood. VWC domains have been identified in more than 70 
extracellular human proteins and seem to represent one of the most abundant protein 
modules. So far, only one structure of a VWC domain－the BMP-binding VWC domain 
of procollagen IIA, has been determined by NMR spectroscopy (O'Leary et al., 2004). 
But in that study, no possible binding epitopes were proposed and no binding activity for 
BMP was shown for the VWC domain used. VWC-containing proteins have different 
specificities and affinities for different BMPs. Therefore, different binding epitopes are 
likely to exist on the BMPs. To better understand the regulatory mechanisms of these 
proteins, it is necessary to know how these binding epitopes are constructed, how they 
overlap with the receptor-binding wrist and knuckle epitopes, and whether inhibitors 
could be generated for each type specifically. 
In this article, the VWC domain-containing protein CHL2 was selected to study the 
structural basis of BMP-2/VWC protein interaction. The VWC domains in CHL2 that are 
involved in BMP binding are determined. The binding affinities, specificities and binding 
epitopes of BMP-2 for CHL2 and the interaction of CHL2/BMP-2 and Tsg, which is a 
novel partner of CHL2, were analyzed in detail. The isolation and crystallization of the 
complex of BMP-2 and CHL2 or its individual VWC domains hopefully will pave the 
way to solve the structures of these proteins. 
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2. Materials and Methods 
 
The experiments described have been performed in the department of Physiological 
Chemistry II, University of Wuerzburg. 
 
2.1 Abbreviations 
 
ActR-IIB Activin Type IIB Receptor 
ALP alkaline phosphatase  
APS ammonium persulfate 
BMPR-IA Bone Morphogenetic Protein Receptor Type IA 
bp base pair 
cDNA complementary deoxyribonucleic acid 
CHL2 Chordin-like 2 
Da Dalton 
DNA deoxyribonucleic acid 
dNTPs deoxyribonucleoside triphosphates 
dsDNA double-stranded deoxyribonucleic acid 
DTT 1,4-dithiothreitol 
E.coli Escherischia coli 
EDTA ethylene diamine tetraacetic acid 
FCS fetal calf serum 
GDF  Growth and Differentation Factor 
HPLC  high pressure liquid chromatography 
KD dissociation equilibrium constant 
Koff dissociation rate constant 
Kon association rate constant 
LB Luria Broth 
mCHL2 Mouse Chordin-like 2 
min minute(s) 
 27
MTT thiazolyl blue tetrazolium 
MS molecular standard 
OD optical density 
PAGE  polyacrylamide gel electrophoresis 
PCR polymerase chain reaction 
PEG polyethylene glycol 
pfu plaque forming unit(s) 
rpm revolutions per minute 
RT room temperature 
SDS sodium dodecyl sulfate 
SF9 Spodoptera frugiperda 9 
ssDNA single-stranded deoxyribonucleic acid 
β-ME β-Mercapoethanol 
TB Terrific Broth 
TCA trichloroacetic acid 
TEMED N,N,N’,N’-tetramethylethylenediamine 
TFA trifluoroacetic acid 
TGF-β Transforming Growth Factorβ 
  
 
2.2 Chemicals 
 
Basic chemicals of highest purity were purchased from Amersham, Biorad, Biolabs, 
Fluka, Gibco-BRL, Merck, NEB, Pharmacia, Promega, Pharmingen, Roth, Sigma. 
All solutions were prepared using deionized water of millipore quality. 
 
2.3 Enzymes 
Restriction endonucleases MBI Fermentas 
RNase Roth/Sigma 
Shrimp alkaline phosphatase (SAP) Roche 
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T4-DNA Ligase MBI Fermentas 
DNA Polymerases MBI Fermentas 
2.4 Kits 
DNA Preparation QIAGEN® Plasmid Kits，QIAGEN 
Gel Extraction Wizard® SV Gel and PCR Clean-Up System, PROMEGA 
DNA Sequencing CEQ™ DTCS-QUICK Start Kit, BECKMAN 
 
2.5 Vectors and oligonucleotides 
 
2.5.1 Expression vector QKA for E.coil 
 
QKA is a modified expression vector based on two old vectors, pQE-80L and pET-24a, 
for the cloning and expression of recombinant proteins in E.coli. It was constructed by 
replacing ampicillin resistance encoding sequence of pQE-80L vector with kanamycin 
resistance encoding sequence which came from pET-24a vector. 
 
2.5.2 Baculovirus transfer vector pAcGP67-B/Th 
 
The Baculovirus transfer vector pAcGP67-B/Th (Pharmingen) provides a gp67 signal 
peptide, a thrombin cleavage site and C-terminal a 6x His-tag in frame with Bam HI. 
After co-transfection with Baculovirus DNA into SF9 cells, the cloned gene is expressed 
as a gp67 signal peptide fusion protein under the control of the strong Baculovirus 
polyhedron promoter. 
 
2.5.3 Oligonucleotides 
 
Oligonucleotides were synthesized and purchased by the MWG-Biotech Inc. in HPLC 
quality. Primers used for PCR mutagenesis, sequencing and PCR reactions are listed in 
the Table 2.1. 
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Table 2.1: Function and sequence of the used Oligonucleotides 
Cloning of mCHL2 and mCHL2-VWC2, VWC3 to pAcGP67-B/Th/m 
EXM-s 5’-GTTGCTGATATCATGGAGATAA-3’ 
PAC-a 5’-TCCCAGGAAAGGATCAGATCTG-3’ 
PAC-Gs 5’-TCTAGAGCTGAGCAGGCCTTTGGTCCCTCGAGGAAGC-3’ 
PAC-Ga 5’-AGGCCTGCTCAGCTCTAGAAAGATCCGCCGCAAAGGC-3’ 
CHL-s 5’-GCGTCTAGACGATCCCGCTCGGGCAAAG-3’ 
CHL-a 5’-GCGAGGCCTTAATGTCTTGGTCACTTTG-3’ 
P-CR2s 5’-GACTCTAGAGTGGATCCTCATGTCCCC-3’ 
P-CR2a 5’-CTCAGGCCTCTCTCCATGCTGCAGCTG-3’ 
P-CR3s 5’-GACTCTAGATCAGTAGGAATGGGCAGC-3’ 
P-CR3a 5’-CTCAGGCCTCCGGGTGGAAATGACCTC-3’ 
 
Cloning of mCHL2-VWC1, VWC3 to QKA 
QKA-5’ 5’-GGCTCATAACACCCCTTG-3’ 
Q-CR1-Sa 5’-TTTGCCCGAGCGGGATCGAGCCATGGTTAATTTCTC-3’ 
Q-CR1-Ss 5’-GAGAAATTAACCATGGCTCGATCCCGCTCGGGCAAA-3’ 
Q-CR1-a1 5’-GCCAGAGGGGACATGAGGGTCCACACACCT-3’ 
Q-CR1-a2 5’-TCTGGATCCCTATTAGCCAGAGGGGACATGAGG-3’ 
Q-CR3-Sa 5’-AGCTTTTTTATGTTTCTCCATGGTTAATTTCTCCT-3’ 
Q-CR3-Ss 5’-AGGAGAAATTAACCATGGAGAAACATAAAAAAGCT-3’ 
Q-CR3-a 5’-ACTGGATCCCTATTACGCCTCGTCCTCAGGGCA-3’ 
  
Site directed Mutagenesis of mCHL2 
CHL-1s 5’-TGCTCACAGCCTGTGATG-3’ 
CHL-2s 5’-CTGCCAGCTCCAGGAGACCACA-3’ 
CHL-3a 5’-TGTGGTCTCCTGGAGCTGGCAG-3’ 
CHL-4s 5’-CACAGAAGAACAGTTGACACAG-3’ 
CHL-5a 5’-CTGTGTCAACTGTTCTTCTGTG-3’ 
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CHL-6a 5’-TGGCGTGCTGGGGCCTCT-3’ 
  
Site directed Mutagenesis of mCHL2-VWC3 
CR3-M1s 5’-GGAGGTGTGGGACCCCACTGT-3’ 
CR3-M1a 5’-ACAGTGGGGTCCCACACCTCC-3’ 
CR3-M2s 5’-GTGTGGCACCGCACTGTGCTC-3’ 
CR3-M2a 5’-GAGCACAGTGCGGTGCCACAC-3’ 
CR3-M3s 5’-ACACAATGGGGACACATACTCCC-3’ 
CR3-M3a 5’-GGGAGTATGTGTCCCCATTGTGT-3’ 
CR3-M4s 5’-CACCCCACTGACCTCTCCTTTG-3’ 
CR3-M4a 5’-CAAAGGAGAGGTCAGTGGGGTG-3’ 
CR3-M5s 5’-CACTGTGCTCGCCTTTGGCCC-3’ 
CR3-M5a 5’-GGGCCAAAGGCGAGCACAGTG-3’ 
CR3-M6s 5’-CTCTCCTTTGCCCCCATGCCC-3’ 
CR3-M6a 5’-GGGCATGGGGGCAAAGGAGAG-3’ 
CR3-M7s 5’-AAAGTGGCTGACAAGTGCTGCA-3’ 
CR3-M7a 5’-TGCAGCACTTGTCAGCCACTTT-3’ 
 
2.6 Bacterial strain 
 
The following genotype E. coli was used: 
 
MM294: ATCC 39607 F- supE44 hsdR17 endA1 thi-1 lambda 
 
2.7 Cell line 
 
SF9 cell line - a cell line, which was originally established from ovarian tissues of 
Spodoptera frugiperda larvae (Vaughn et al., 1977). SF9 cells may be grown in a 
monolayer or in a suspension. 
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2.8 BMP-2 
 
BMP-2: Recombinant BMP-2 was a generous gift from Prof. W. Sebald, Wuerzburg.
 
2.9 Antibodies 
 
For detection of Western Blot, the following antibodies were used: 
Anti-His-tag McAb  (QIAGEN) 
Pod goat-Anti-mouse (Sigma) 
 
2.10 Microbiological methods 
 
2.10.1 Sterilization 
 
Glasswares and other experimental materials were sterilized at 180 ℃ for 6 hours in a 
hot-air-cabinet (Heraeus, ST5060). Buffers, media and plastic containers were autoclaved 
(Sterico Vapoclav steam-sterilisator) at 121 ℃ and 1.1 bar for 20 min. Solutions of 
temperature-unstable substances were sterilized by filtering through Millipore-Filter 
(MILLEX® GP, 0.22 μm, MILLPORE). 
 
2.10.2 Culture media 
 
LB-medium 
10 g/L 
5 g/L 
10 g/L 
Peptone 
Yeast extract 
NaCL 
Sterilized by autoclaving 
 
LB-antibiotic plate 
10 g/L 
5 g/L 
10g/L 
15% 
Peptone 
Yeast extract 
NaCL 
Agar 
The final concentration of antibiotics: 
Ampicillin: 50ug/ml 
Kanamycin: 30ug/ml 
Tetracycline: 12.5ug/ml 
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Sterilized by autoclaving. When the agarose solution was cooled to 50℃, 
the antibiotics were added. After mixing, the agarose solution was filled 
into plates, cooled at RT and kept at 4℃ 
 
TB-medium 10x Pi Buffer 
13.3 g/L 
26.6 g/L 
4.4 ml/L 
Peptone 
Yeast extract 
Glycerin 
0.17 M 
0.72 M 
KH2PO4 
K2HPO4 
Sterilized by autoclaving Sterilized by autoclaving 
 
2.10.3 Culturing of bacteria 
 
Glycerin stock-culture was spread over an agar plate and incubated at 37℃ overnight. A 
colony was picked up and incubated in 2 ml of medium at 37℃ for a day. This culture 
was further used for making larger culture. 
 
2.10.4 Storage of bacterial culture 
 
For short-term bacterial storage, 10 μl of glycerin stock-culture of bacteria was spread 
over an agar plate and incubated at 37℃ overnight until colonies appeared. Such a plate 
can be kept for 4 to 6 weeks at 4℃. 
For long-term bacterial storage, a single bacterial colony was cultivated in 50 ml of 
LB-medium with antibiotics at 37℃ until the suspension reached OD550 of 0.5. The 
following centrifugation was carried out at 4000 rpm for 10 min at 4℃. Then the pellet 
was washed with 40ml cold LB-medium for 2 times and resuspended in 1ml of 
LB-medium/antibiotics mixed with 1ml of sterilized glycerol. This culture can be kept at 
-20℃ for several years. 
 
2.10.5 Preparation of competent E.coli cells 
Materials 
Clean Bench Heraeus LaminAir® HBB 2448 S 
Millipore-Filter MILLEX® GP, 0.22 μm, MILLPORE 
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TBS buffer 
 
85% LB medium, 10% PEG8000, 5% DMSO, 50mM MgCL2 
(pH6.5). TBS was treated by Millipore-Filter, and pre-cooled at 4℃. 
 
Procedure 
E.coli MM294 colonies were picked off a freshly streaked plate derived from a frozen 
stock stored at -20℃ and put into 2ml of LB medium in clean bench and incubated at 
37℃ for 2h. Then the 2ml of LB medium was added to 100ml LB medium and incubated 
at 37℃ to OD 0.5. The culture was kept on ice for 5 min, and then transferred to two 
sterilized 50 ml Falcon-tubes followed by a centrifugation at 4000 rpm for 10min. For 
each tube the pellet was resuspended carefully in 10ml of TBS buffer. The competent cell 
suspension was aliquoted 200μl into the polypropylene tubes and put into liquid nitrogen 
for 20 sec. At the last the competent cell was kept at -80 ℃. 
 
2.11 Molecular biological methods 
 
2.11.1 Site directed mutagenesis by PCR 
 
Most of the mutations were generated by using a two-step polymerase chain reaction. The 
first step was performed in two different reactions - reaction la and reaction lb. In reaction 
la (Figure 2.1; Table 2.2) the primer 2 carries the target mutation and the primer 1 is 
external. The primer 3, which was used in reaction lb, was mutated and complementary to 
the prime 2 in reaction la. The primer 4 in reaction lb was external. 
 
Figure 2.1: Two-step PCR procedure. Two-step PCR was used to generate a mutational cDNA 
which was synthesized during the second step of the PCR to gain the target mutation. P1 - P4, 
primer 1-4. 
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Table 2.2: PCR - reaction la and reaction lb 
 Reaction la Reaction lb 
template 50 ng 50 ng 
mutant primer 50 pmol (primer 2) 50 pmol (primer 3) 
external primer 50 pmol (primer 1) 50 pmol (primer 4) 
dNTPs l0 nmol 10 nmol 
10 x Pfu polymerase buffer 5 μl 5 μl 
Pfu polymerase 2.5 U 2.5 U 
H20 to 50 μl to 50 μl 
 
The synthesized products from reaction la and lb were analyzed by an agarose gel and 
directly used as a template during the second step of the PCR generated mutagenesis. This 
recombinant PCR was performed with the two external primers used in the first step: the 
primer 1 from reaction la and the primer 4 from reaction lb (Figure 2.1; Table 2.3). 
 
Table 2.3: Second step of PCR generated mutagenesis 
 Reaction 2 
reaction product la 2 μl template 
reaction product lb 2 μl 
primer 1 (from reaction la) 100 pmol 
primer 4 (from reaction lb) 100 pmol 
dNTPs 20 nmol 
10 x Pfu polymerase buffer 10 μl 
Pfu polymerase 5 U 
H20 to 100 μl 
 
All reactions were performed in safe-lock Eppendorf tubes with the following program 
(Table 2.4): 
Table 2.4: PCR Program 
 PCR-Program  
Step Temperature, Time Cycles 
Initial denaturation 95℃, 6 min 1 
Melting 94℃, 1 min 
Annealing 55℃, 1 min 
Elongation 72℃, 1 – 2 min 
25-30 
Final extension 72℃, 10 min 1 
Soak  4℃, ∞ 1 
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The product which was synthesized during the second step of the PCR contains the 
mutation of choice. After visualization on agarose gel, it was purified by 
Phenol/chloroform extraction and Ethanol precipitation for the further experiments. 
 
2.11.2 Determination of the concentration of nucleic acids 
 
The concentration of DNA can be roughly estimated by using an agarose gel 
electrophoresis. For amounts less than 200 ng, the fluorescence of the ethidium bromide, 
incorporated in the DNA fragments is proportional to the concentration of DNA. The 
intensity of the examined bands was compared to this of the DNA standards with known 
concentrations. 
The concentration of nucleic acids also can be measured by spectrophotometry in the 
absorption spectrum range 240-320 nm. (CARY 50 Bio, UV-visible Spectrophotometer, 
VARIAN). Considering an extinction value of 1, the relation between A260 and the 
concentrations is shown as follows: 
Nucleic acids Concentration
dsDNA 
ssDNA 
Oligonucleotide
50ug/ml 
33 ug/ml 
20ug/ml 
 
2.11.3 Purification of DNA  
 
2.11.3.1 Phenol/Chloroform extraction of DNA 
The DNA containing fraction was mixed with the phenol (2:1 Vol.) adequately and later 
treated with chloroform (2:1 Vol.). After centrifuged at 15000 rpm for 5 min, the aqueous 
phase was transferred to a new tube. The aqueous phase was mixed with chloroform (1:1 
Vol.), and the new aqueous phase was transferred to a new tube after centrifuged at 15000 
rpm for 5 min. 
 
2.11.3.2 Ethanol precipitation of DNA 
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DNA solutions were precipitated by adding 3M NaOAc/pH 8.0 (10:1 Vol.) and 100% 
cold ethanol (1:2.5 Vol.). The sample was thoroughly vortexed, incubated for 60 min at 
-20℃ and centrifuged (10min, 15000 rpm). The pellet was washed with 70% cold ethanol 
and dried under vacuum. The pellet was dissolved in desired volume sterile dH2O or TE 
buffer. 
 
2.11.3.3 Gel extraction kit for DNA purification 
After 2% agarose gel electrophoresis, the target DNA band was cut off on UV light panel 
and treated with the standard protocol of the Wizard® SV Gel and PCR Clean-Up System 
kit (PROMEGA). 
 
2.11.4 Digestion of DNA 
 
All restriction reactions were performed in the presence of recommended 10x reaction 
buffer. For analytical purposes, 100-500 ng DNA were digested in reaction volume of 10 
μl, using 1-10 U restriction endonucleases. The reaction mix was incubated for 1 h at 
37℃ and stopped by incubated at 65℃ for 30 min. Then 2-4 μl were examined by agarose 
gel electrophoresis. The DNA was purified by agarose gel electrophoresis and gel 
extraction kit, before it was used for ligation reaction. 
 
2.11.5 Ligation of DNA to the vector 
 
Materials 
T4 DNA ligase, 10x T4 DNA ligase buffer (MBI) 
 
Procedure 
The vector/insert’s molar ration of 1:3 was determined to be optimal. The total amount of 
DNA for cloning was 200ng per 10μl reaction volume. The reaction mixture, containing 
1-5 U of T4 DNA ligases was incubated for 12-16 h (or overnight) at RT. The reaction 
was stopped by incubated at 65℃ for 30 min. 10% samples from the ligation mixture 
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were loaded on an agarose gel to examine the reaction efficiency. The other recombinant 
plasmid DNA was directly used to transform to competent E.coli. Otherwise, it can be 
stored at -20℃. 
 
2.11.6 Transformation of recombinant plasmid DNA to competent E.coli 
 
10μl of DNA solution (DNA 50-100ng) were added to 200 μl aliquot of competent cell 
suspension and this mixture was incubated on ice for 30 min. A heat-shock was made at 
42℃ for 90 sec. After kept on ice for 2 min., 800 μl of LB medium was added and the 
mixture was continually incubated at 37℃ for 1h. Then the transformed cell suspension 
was plated separately to antibiotic-plates with both a positive control and a negative 
control. The positive control was 0.1μg recombinant plasmid DNA transformed E coli 
cells and the negative control was 1-10ng linear vector transformed cells. The plates were 
incubated at 37 ℃ overnight to develop colonies of the transformed cells. 
 
2.11.7 Mini-preparation of recombinant plasmid DNA 
 
Materials 
P1-Buffer: 50 mM, Tris/HCl, pH 8.0; l0 mM, EDTA 
P2-Buffer: 0.2 M NaOH; l % (w/v) SDS 
P3-Buffer: 2.8 M KAc, pH 5.1 
 
Procedure 
1. Inoculate a single colony in 5ml LB-Medium and incubate at 37℃ overnight with 
shaking. 
2. Collect cells by centrifugation at 10000 rpm for 5 min at RT and remove 
supernatant. 
3. Resuspend bacterial pellet in 200μl P1-Buffer and then mix 300μl of P2-Buffer 
gently by inverting tube 6-8 times and incubate on ice for 5 min. Do not vortex to 
prevent the release of chromosomal DNA from the cell debris. Bacterial cells are 
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lysed by a NaOH/SDS solution. Chromosomal and plasmid DNA are denatured 
under this alkaline condition. It is important to control the duration of this step 
thoroughly. 
4. Add 300μl of P3-Buffer for neutralization and mix like described above until a 
homogenous suspension is formed. Incubate on ice for 5 min. This step results in 
a precipitation of SDS, chromosomal DNA and other cellular compounds. 
Plasmid DNA stays in solution and reanneals to its supercoiled structure. 
5. Centrifuge at 15000 rpm for 15 min at 4℃. 
6. Transfer supernatant to a new cap and use Phenol/Chloroform Extraction method 
to purify the Plasmid DNA. 
7. Precipitate DNA by adding 700μl of 2-propanol and centrifuge for 10 min at RT, 
15000 rpm. 
8. Rinse pellet twice with 70% Ethanol. 
9. Briefly dry pellet (about 5 min at RT) with vacuum. 
10. Resuspend DNA in 20μl water or suitable buffer. 
 
2.11.8 Maxi-preparation of recombinant plasmid DNA  
 
Materials 
QIAGEN® Plasmid Kits，QIAGEN 
 
Procedure 
1. Inoculate a single colony in 2ml LB medium and incubate at 37℃ overday with 
shaking. Then transfer the 2ml bacterial solution to 200 ml LB medium and 
incubate at 37℃ overnight with shaking. 
2. Collect cells by centrifugation at 10000 x g for 5 min at RT and remove 
supernatant. 
3. Bacterial pellet was treated by the protocol of QIAGEN® Plasmid Kit. 
4. Rinse pellet with 70% Ethanol and dry the pellet with vacuum pump. 
5. Resuspend DNA in 100μl water or suitable buffer. 
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2.11.9  DNA sequencing 
 
Materials 
CEQ™ DTCS-QUICK Start Kit, BECKMAN 
 
Procedure 
According to manufacturer's protocol, sequencing PCR was performed with the Quick 
Start Mix of the CEQ™ DTCS-QUICK Start Kit followed the programs: 
 
98 ℃ 96 ℃ 50 ℃ 65 ℃ 4 ℃ 
0.2 min 0.2 min 4 min 
2 min 
30 cycles 
Keep 
 
The DNA sequencing was performed by Beckman CEQ2000 automated DNA sequencer. 
The used method, according to Sanger, relies on the base-specific termination of the DNA 
chain elongation by random integration of labeled ddNTPs at the end of the chain. Four 
independent sequencing reactions were carried out for each analyzed DNA sample. Each 
reaction contained different chain-terminating ddNTP coupled to a corresponding 
fluorescent day. Due to the different fluorescence, the single DNA fragments could be 
detected by an argon laser beam. 
 
2.12 Protein chemical methods 
 
2.12.1 Determination of the protein concentration 
 
The concentration of a protein solution can be measured by spectrophotometry at the 
absorption spectrum range 250-320 nm (CARY 50 Bio, UV-visible Spectrophotometer, 
VARIAN). The absorbency value A at 280 nm was used for calculation. The 
concentrations of mCHL2, mCHL2-VWC1, VWC2, and VWC3 proteins per absorbency 
unit (A280 =1) and the path length equal to 1 cm are shown in the Table 2.5. 
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Table 2.5: Molar absorbency factor and concentration of mCHL2 and mCHL2-VWC1, VWC2, VWC3 
 
Protein Extinction coefficients 
(280nm) [mol-1.cm-1] 
Concentration per absorbency unit 1 
[mg/ml] 
mCHL2 41320 1.13 
mCHL2-VWC1 12085 0.74 
mCHL2-VWC2 3605 3.02 
mCHL2-VWC3 10130 0.79 
BMP-2 25791 0.68 
 
2.12.2 Lyophilization of proteins 
 
The purified protein was extensively dialysed against H2O and frozen at -70℃ overnight. 
The frozen protein were then transferred to the Lyophilizator (LDC-1, CHRIST), which 
was pre-cooled to -55℃ and vacuum pumped to 0.02 bar overnight. 
 
2.12.3 SDS - polyacrylamide gel electrophoresis 
 
Materials 
acrylamide solution 30% acrylamide, 0.8% N,N'-methylenbisacrylamide 
4 x lower Tris 1.5M Tris-HCl, 0.4% SDS, pH 8.8 
4 x upper Tris 0.5M Tris-HCl, 0.4% SDS, pH 6.8 
glycerol 87% glycerol 
Free radicals catalyst TEMED 
polymerization initiator 40% APS  
SDS running buffer 25mM Tris-HCl pH 8.6, 190mM glycin, 0.15% SDS 
SDS sample buffer 62.5mM Tris-HCl pH 6.8, 2% SDS, 20% glycerol. 
 2% BPB, 2% β-mercaptoethanol 
staining solutuion 0.25% Coomassie Brilliant Blue R2S0 in destaining solution
destaining solution 1 Vol. acetic acid, 1 Vol. isopropanol, 8 Vol. H2O 
 41
Procedure 
In SDS-polyacrylamide gels, the proteins were separated by their molecular weight. The 
electrophoresis was performed in a vertical gel electrophoresis system Mini-V 8.10 
(Gibco BRL). Different acrylamide concentrations can be used for different gel 
preparations depending on the size of the separated proteins. The separating gel solution 
was decanted between two vertical glass-slabs (layer thickness 0.75 mm) with a Pasteur 
pipette to 2/3 of the glasses upper edge and then covered with a water layer. After 
polymerization, the water was poured out, the stacking gel solution was filled on the top 
and a comb was immediately inserted. 
The protein samples and SDS sample buffer (1:1) were mixed and boiled at 100℃ for 5 
min. A microlitre syringe was used to place the protein solutions in the wells of the slab. 
For each well 0.5-2 pg of protein was loaded. In the first lane, parallel to the samples, the 
protein standard was loaded. Until the samples were concentrating, the gels were running 
at 170 -200V. 
After the end of the electrophoresis, the gel was placed for 30 min in a coomassie solution 
for staining. The destaining was done for more than 2h. The ready gel was kept 1 h in 20 
% methanol and dried between two pieces of cellophane. 
 
2.12.4 Concentration of protein samples by TCA 
 
Materials 
50% TCA, 100% ethanol, 1 M Tris-HCl (pH 8.0) 
 
Procedure 
When the protein concentration was low, concentration by 50% TCA was done before the 
sample was loaded on SDS-PAGE. 50% TCA (4:1 Vol.) and 100% ethanol (4:1 Vol.) was 
added to the protein sample. After mixing, the protein solution was incubated for 10 min 
on ice and then centriftiged for 10 min at 15000 rpm (Eppendorf Centrifuge). The pellet 
was dissolved in desired volume of SDS sample buffer. The yellow color of the solution 
indicates an acidic pH condition. Then 1μl of 1M Tris-HCl (pH 8.0) was added to 
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neutralize the acidic pH. 
 
2.12.5 Protein mass spectroscopy 
 
The precise molecular weight of protein was determined with a help of Dr. Werner 
Schmizt and Pro. Ernst Conzelman by the method of Fourier Transform-Ion Cyclotron 
Resonance mass spectroscopy. A detailed description of the method is available from Dr. 
Werner Schmizt upon request. 
 
2.13 Western-Blot 
 
Western blotting was used to verify the expression of mCHL2 by SF9 cells, after the 
second step of virus amplification. 
 
Material: 
Transfer buffer 25 mM Tris, 192 mM glycin, 20% methanol 
3% milk solution 3g Skim Milk Powder (Fluka), 100μl Tween 
100 ml TBS: 100 mM Tris, 150 mM NaCl, pH 7.5 
Primary antibody Anti-His-tag McAb (QIAGEN) 
Secondary antibody Pod goat-Anti-mouse (Sigma) 
  
Buffer A 5ml 0.1M, Tris, pH 8.5, 6 μl H2O2 
Buffer B 5ml Luminol (2.5 mM 3-Aminophthalhydrazide in 0.1 
mM, pH8.5 Tris and 1% DMSO) , 22μl Enhancer (90 
mM P-cumaric acid in 100% DMSO) 
 
Nitrocellulose membrane ,  Whatman paper 
Blotting apparatus   Blot Module Mini-V8.10, Gibco BRL 
 
Procedure 
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1. Collect virus solution of Second virus amplification (A2). Then centrifugate at 1000 
rpm for 5 min and collect the supernatant. 
2. 10 μl of A2 virus supernatant mixed with equal volume of protein loading buffer was 
electrophoretically separated on a SDS polyacrylamide gel. The negative control was 
used a sample of equal volume, which contained only the medium for SF9 cells. The 
positive control was a sample of Chordin VWC1 with His tag (which was expressed 
by SF9 cell before) with known concentration. 
Wet a Nitrocellulose membrane in water for 2 min and then in transfer buffer for 5 
min with two pieces of Whatman papers and transfer pads. The gel and its attached 
Nitrocellulose membrane were sandwiched between two pieces of Whatman papers 
and two transfer pads. To be sure there were no air bubbles between gel and 
nitrocellulose membrane. The blotting apparatus, containing the ‘sandwich’, was 
placed in electrophoresis chamber filled with transfer buffer. The nitrocellulose 
membrane was toward to anode. Then transfer for 1 hour at 150 V. At this step, the 
proteins were transferred from gel to the nitrocellulose membrane. 
3. Block 
3.1 Wash the nitrocellulose membrane 2 times with TBS buffer for 10 min. 
3.2 Incubate the nitrocellulose membrane in 10 ml milk solution for 1 hour at RT or 
alternatively overnight at 4℃ (Remain shaking). 
4. Primary antibody 
Incubate the nitrocellulose membrane in 7 ml milk solution with 7 μl primary 
antibody (diluted 1: 1000-2000 in milk solution) for 1 hour at RT or alternatively 
overnight at 4℃ (Remain shaking). 
5. Secondary antibody 
5.1 Wash the nitrocellulose membrane 3 times with 10 ml milk solution for 10 min. 
5.2 Incubate the nitrocellulose membrane in 7 ml milk solution with 3.5 μl secondary 
antibody (diluted 1: 5000-10000 in milk solution) for 1 hour at RT (Remain 
shaking). 
5.3 Wash the nitrocellulose membrane 3 times with 10 ml milk solution for 10 min 
and dry. 
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6. In dark room, mix buffer A and buffer B. Then incubate the nitrocellulose membrane 
in the mixed solution for 3 min at RT. The nitrocellulose membrane was shortly dried, 
exposed to an X-ray film for 5 seconds. At the last the film was developed. 
 
2.14 Expression of recombinant protein in E.coli 
 
2.14.1 Analytical protein expression 
 
Analytical protein expression should be used prior to large-scale purification to check 
clones for expression of the desired protein with help of SDS-PSGE analysis. 
 
Materials 
LB-medium (Antibiotics are added depends on expression vector and bacterial host.) 
100 mM IPTG stock solution, 2x SDS loading buffer 
 
Procedure 
1. Inoculate a single, well isolated colony of E. coli transformed with the recombinants 
into separate tubes containing 2 ml of LB-medium plus necessary antibiotics. 
2. Grow liquid cultures to an OD550 of 0.6-0.8 (3-5 hours) with vigorous agitation at 
30-37 ℃. 
3. Take 1ml of non-induced bacterial culture for later control in SDS-PAGE analysis. 
4. Induce protein expression by adding 10 μl of 100 mM IPTG (final concentration is 1 
mM) to 1ml bacterial culture. 
5. Continue incubation for an additional 3 h. 
6. Centrifuge 100μl control and induced sample in a microcentrifuge for 1 min. at 
15000 rpm, discard the supernatants.  
7. Dilute the disrupted cells in 30μl 2x SDS loading buffer. 
8. The protein expression rate was investigated with SDS-PAGE analysis and could be 
quantitatively evaluated by scanning densitometry. 
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2.14.2 Preparative protein expression 
 
Materials 
LB-medium, TB-medium (antibiotics are added depending on expression vector and 
bacterial host) 
 
Procedure 
1. Overday culture  
1.1 Inoculate a single, well isolated clone of E.coli transformed with the recombinant 
into glass tube containing 2 ml of LB-medium plus necessary antibiotics. 
1.2 Incubate for 3-4 hours at 37℃ with vigorous shaking. 
2. Overnight culture 
Dilute the overday culture into 240 ml LB-medium plus necessary antibiotics at 37℃ 
with shaking over night. 
3. Fermentation 
3.1 Add 720 ml TB medium, 80 ml 10xPi, 20-40 ml Overnight culture and necessary 
antibiotics into an Erlenmeyer flask. 
3.2 Cultivate the cells at 37℃ until they reach early states of logarithmic growth phase 
(OD550 0.5-0.7). 
3.3 Add IPTG (1mM) to cells and cultivate continuously for an additional 3-4 hours. 
4. Harvest  
4.1 Transfer the culture to JA-10 centrifuge beakers and Centrifugate at 6000 rpm for 
20 min at 4℃. 
4.2 Resuspend the pellet with TBSE buffer plus β-ME (1:1000 dilute) and 
Centrifugate at 6000 rpm for 20 min at 4℃ again. 
4.3 Freeze the cells at -20℃. 
 
2.14.3 Preparation of inclusion bodies 
 
Materials 
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TBSE Buffer 10 mM Tris, 150 mM NaCL, 1 mM EDTA, pH 8.0 
PMSF stock 100 mM PMSF (Phenylmethylsulphonylfluoride) in isopropanol
 
Procedure 
1. Resuspend 20g cell pellet in 200 ml PMSFMETBSE −β  (1mM PMSF, 1:1000 diluted β-ME), 
and sonicate the cells for 5 min at 300 Watt on ice. 
2. Centrifugate in JA-14 beakers at 11500 rpm for 30 min at 4℃. 
3. Resuspend the pellet with PMSFMETBSE −β  again. 
4. Sonicate the cells for 3 min at 300 Watt on ice. 
5. Resuspend and wash the inclusion bodies with METBSE −β  and centrifugate in JA-14 
beakers at 11500 rpm for 30 min at 4℃. 
6. Remain the sediment (inclusion bodies) at -20℃. 
 
2.14.4 Denaturation and refolding of protein 
 
Materials 
6 M GuHCl 6 M Guanidin HCl, 50 mM NaOAC, 1 mM EDTA, pH 5.0 
8 M GuHCl 8 M Guanidin HCl, 50 mM NaOAC, 1 mM EDTA, pH 5.0 
50 mM NaOAC pH 5.0 
DTT  stock 0.5M, DTT (1,4-Dithiothreit) in ethanol 
Refolding Buffer 2 M LiCL, 50 mM Tris, 25 mM Chaps, 5 mM EDTA, 3 mM 
L-Glutathion red., 1 mM L-Glutathion ox. 
S300 size exclusion 
chromatography 
Pump: LKB 2232 Microperpex S peristaltic Pump 
Collector: LKB 2211 Superrac 
Detector: LKB 2238 Uvicord SII 
Recorder: LKB 2210 Recorder 
Column: 2.6 x 63 cm (Pharmacia) 
Column material: SephacrylTM  S-300 High Resolution (Phamarcia)
 
Procedure 
1. Weight inclusion bodies and resuspend them in 8 vol. (v/w) 50 mM NaOAc, pH5.0. 
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Add 1 vol. (v/w) 6M GuHCl plus β-ME (1:1000 dilute) and stir for 30 min at room 
temperature. The inclusion bodies were washed in 0.6M GuHCl in this step. 
2. Centrifugate in JA-14 beakers at 11500 rpm for 20 min at 4℃. 
3. Denaturation of protein 
3.1 Weight the pellets and resuspend them in 2.5 vol. (v/w), 50mM NaOAc, and pH5.0. 
Add 7.5vol. (v/w), 8M GuHCl plus β-ME (1:1000 dilute) and stir for 30min at RT. 
The final concentration of GuHCl was 6 M. 
3.2 Centrifugate in 45Ti rotor at 30000 rpm for 60 min at 18℃, and collect the 
supernatant. 
3.3 Purify the extract by size-exclusion chromatography on Sephacryl S300. Apply 
not more than 20 ml of the extract per run. 
3.4 Analyze every peak fraction by SDS-PAGE, and select the target peak fraction. 
3.5 Concentrate the denatured protein solution on Amican® to the final absorbency of 
20 OD. 
4. The denatured protein was diluted 100 times with the refolding buffer and incubated at 
4℃ for 7 days. 
5. Dialyse the refolding protein with 20 mM Tris, 20 mM NaCl, pH 7.4 for the next step. 
 
2.15 Expression of protein in SF9 cells 
 
2.15.1 Co-transfection of BaculoGold DNA and a transfer vector into SF9 cells  
 
Materials 
Linearized BaculoGold Baculovirus DNA 
Transfection buffer A 
BaculoGold Transfer Kit  
(BD Biosciences Pharmingen): 
Transfection buffer B 
FCS (Biochrom KG) 
SF9-medium (Hyclone®, Perbio Science Company) 
Confluent monolayer culture of SF9 cells 
Transfer vector  
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6-well tissue culture plate (Greiner Bio-One) 
 
Procedure 
1. Ethanol Precipitation of a transfer vector 
1.1 Mix 5μl of a transfer vector (about 5ug), 40μl H2O, 5μl 3M NaOAc (pH 4.8) and 
100μl ethanol, and incubate at -20 ℃ for 1 hour. 
1.2 Centrifugate at 15000 rpm for 10 min and Wash the pellet with 200 μl of 70% ethanol. 
1.3 Centrifugate at 15000rpm for 5 min and Dry in clean bench. 
2. Adjust SF9 cell density to 0.8 x 106 cells/ml with 10% FCS SF9-medium. 
3. Add 1 ml cell and 1 ml medium to each well of 6-well tissue culture plate, and 
incubate at 27 ℃ for 1 hour until the cells attach firmly to the bottom. 
4. Remove the medium, and add 500μl of buffer A to each well. 
5. The transfer vector is mixed with 2.5μl of Linearized BaculoGold Baculovirus, and 
then incubated for 5 min at RT. After 5 min of incubation, 500μl of buffer B is added 
to the co-transfection mixture. 
6. Drop by drop, the co-transfection mixture is added to each well of 6-well tissue 
culture plate containing 500μl of buffer A slowly. 
7. The plate is incubated at 27 ℃ for 4 hours. 
8. Remove the medium and wash the cells with 1.5-2 ml fresh medium for 2 times. 
9. The plate is incubated at 27 ℃ for 5 days containing 1 ml fresh medium. 
10. Collect the virus solution and Centrifugate at 1000 rpm for 5 min. 
11. Collect the supernatant, and store at 4℃ in dark. 
 
2.15.2 Plaque-assay for getting single virus clone 
 
Materials 
2.7 %, Plaque Agarose: low melting temperature agarose (Biozym), 
dissolved in H2O, autoclaved and kept at 65℃ 
Confluent monolayer culture of SF9 cells 
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FCS (Biochrom KG) 
SF9-medium (Hyclone®, Perbio Science Company) 
2x Xpress Medium (GIBCO™) 
1 mg/ml, MTT dissolved in distilled water and filtered through 0.22μm filter 
6-well tissue culture plate (Greiner Bio-One) 
 
Procedure 
1. Count cells, and adjust cell density to 1.2 x 106 cells/ml by 10% FCS SF9-medium 
2. Apply 1 ml of cell solution and 1 ml of medium per well. Incubate for 1 hour at 27℃. 
3. Dilute virus solution according to the following rations (1ml per well required): 
1x10-2, 1x10-3, 1x10-4, 1x10-5, and 1x10-6. 
4. Add virus solution to cell (1 ml per well), and incubate for 1 hour at 27℃. 
5. Mix 3.3 ml Agarose (2.7%) with 700μl FCS and 6.6 ml 2x Xpress Medium for each 
plate (6 wells). 
6. Remove medium of step ‘4’, and apply 1.5 ml mixture of step ‘5’ to each well. 
7. After Agarose becoming hardened, close the plate with parafilm and store on a wet 
tissue in a box at 27℃ for 5 days. 
8. Apply 1 ml of MTT (1mg/ml) to each well, and incubate for 1 hour at 27℃ for 
visualizing single clone. 
 
2.15.3 First virus amplification (A1) 
 
Materials 
Confluent monolayer culture of SF9 cells 
FCS (Biochrom KG) 
SF9-medium (Hyclone®, Perbio Science Company) 
6-well tissue culture plate (Greiner Bio-One) 
 
Procedure 
1 Select 6 clones from the plaque, and incubate in 1 ml medium for 1 hour at 27℃. 
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Then Centrifugate at 1000 rpm for 5 min and collect the supernatant. 
2 Count cells and adjust cell density to 1.5x 106. Apply 1 ml of cell solution and 1 ml 
of medium per well in 6-well plate. Incubate for 1 hour at 27℃ (cells attach to 
surface). 
3 Remove medium of step ‘2’, and apply the 1ml of virus solution of step ‘1’ per well. 
4 Incubate for 4 days at 27℃.  
 
2.15.4 Second virus amplification (A2) 
 
Materials 
Confluent monolayer culture of SF9 cells 
FCS (Biochrom KG) 
SF9-medium (Hyclone®, Perbio Science Company) 
6-well tissue culture plate (Greiner Bio-One) 
 
Procedure 
1 Collect A1 and centrifugate at 1000 rpm for 5 min and collect the supernatant. 
2 Count cells and adjust cell density to 1.5x 106. Apply 1 ml of cell solution and 1 ml 
of medium per well. Incubate for 1 hour at 27℃. 
3 Remove medium of step ‘2’, then apply the 1 ml of virus solution of step ‘1’ and 1 ml 
of medium per well. 
4 Incubate for 4 days at 27 ℃. 
 
2.15.5 Western-Blot for positive clone (See 2.13) 
 
2.15.6 Third virus amplification (A3) 
 
Materials 
Confluent monolayer culture of SF9 cells 
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FCS (Biochrom KG) 
SF9-medium (Hyclone®, Perbio Science Company) 
Tissue culture Flask, 175cm2, 550ml (Greiner Bio-One) 
 
Procedure 
Add 2 ml virus solution of positive clone from A2 into flask (175 cm2) with 8 x 107 
cells/ in 30 ml medium, and incubate for 4 days at 27 ℃. 
 
2.15.7 Forth virus amplification (A4) 
 
Materials 
Confluent monolayer culture of SF9 cells 
FCS (Biochrom KG) 
SF9-medium (Hyclone®, Perbio Science Company) 
Roller-bottle (Greiner Bio-One) 
 
Procedure 
1. Collect A3. Then centrifugate at 1000 rpm for 5 min and collect the supernatant. 
2. Add 7.5 ml of A3 into 30 ml cells (1.5 x 106 cells/ml) in roller-bottle, and incubate for 
4 days at 27 ℃. 
3. Determination of A4 virus titers by plaque assay. To be sure the virus titers are above 
5x 107 virus /ml. 
 
2.15.8 Expression 
 
Materials 
Confluent monolayer culture of SF9 cells 
FCS (Biochrom KG) 
SF9-medium (Hyclone®, Perbio Science Company) 
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Roller bottle (Greiner Bio-One) 
 
Procedure 
Add 15 ml A4 (the titers are 5-10x 107) to 200 ml cells (1.5 x 106 cells/ml) in roller 
bottle, and incubate for 4 days at 27℃. The virus/cell ratio was 2-5:1. 
 
2.16 Purification of proteins by chromatography 
 
2.16.1 Ni-NTA chelating chromatography 
 
Materials 
Loading and Wash-buffer 50 mM NaH2PO4, 300 mM NaCl, 10 mM Imidazol, pH 8.3 
Elution buffer 50 mM NaH2PO4, 300 mM NaCl, 300 mM Imidazol, pH 8.3 
Column material Ni-NTA Agarose (QIAGEN®) 
 
Procedure 
1. Mix Ni-NTA solution, and apply 10 ml of Ni-NTA to centrifugate at 500 rpm for 5 
min at RT and remove the supernatant. Then wash the precipitate with 50 ml of wash 
buffer for 2 times. 
2. Mix 5 ml Ni-NAT and 1 liter protein solution together, and stir for 1 hour at 4℃. 
3. Transfer the mixture to column, and wash the column with 20 vol. (v/v) wash buffer. 
4. Elute the column with elution buffer, and collect 5 ml per fraction. Analyse the 
collected fractions with SDS-PAGE and select those containing potential target 
protein. 
5. Dialyse the collected protein solution with 20 mM Tris, 20 mM NaCl, and pH 7.4 for 
the next purification step. 
 
2.16.2 Cation exchange chromatography on SP sepharose 
 
Materials 
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Buffer A 20 mM Tris, pH 7.4 
Buffer B 20 mM Tris, 1M NaCl, pH 7.4 
  
Column 2 x25 cm (GE Health Care) 
Column material SP sepharose™, Fast Flow (GE Health Care) 
  
Detector: L-4200 UV-VIS Detector (Merk-Hitach) 
Pump: L-6200 Intelligent Pump (Merk-Hitach) 
Collector: FC 203B Fraction Collector (GILSON) 
FPLC system 
Recorder: LR 66920 Recorder (Pharmacia) 
 
Procedure 
1. Equilibrate the column with Buffer A with flow rate 1.5 of ml/min. 
2. Apply protein solution to the SP sepharose and wash the column with Buffer A until 
the baseline is constant with flow rate of 1.5 ml/min. 
3. Elute the protein with a linear salt gradient: 0 -1 M NaCl, achieved through mixing 
with Buffer B with flow rate of 1.0 ml/min. Collect 1.5 ml per fraction. Follow the 
elution profile with UV flow photometer, monitoring at wave length of 280 nm. 
       Gradient: 
Time (min) % NaCl 
0 0 
20 30 
80 50 
90 100 
100 0 
4. Analyze the flow through and peak fractions by SDS-PAGE and select those 
containing potential target protein. 
5. Dialyse the collected protein solution with 10 mM HEPES, 500 mM NaCl, pH 7.4 for 
next purification step. 
 
2.16.3 BMP-2 affinity chromatography 
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Materials 
Buffer A 10 mM HEPES, 500 mM NaCl, pH 7.4 
Buffer B 10 mM HEPES, 150 mM NaCl, pH 7.4 
Elution buffer 4 M MgCl2 
  
Affinity Matrix BMP-2 immobilized CNBr-Sepharose 4B 
Column 1x10 cm (Biorad) 
  
Pump: 2232 Microperpex S peristaltic Pump (LKB) 
Detector: 2238 Uvicord SII (LKB) 
Collector: 203 Collector (GILSON) 
Instruments 
Recorder: 2210 Recorder (LKB) 
 
Procedure 
1. Equilibrate the affinity column with Buffer A. 
2. Apply protein solution to column and wash the affinity column with Buffer A until the 
baseline is constant. 
3. Elute active protein which binds to immobilized BMP-2 with 4 M MgCl2. 
4. Collect 8 ml per fraction and measure their OD on UV spectrophotometer. Combine 
fractions carrying active protein and dialyse them against 50 vol. 10 mM HEPES, 500 
mM NaCl for the next purification step. 
 
2.16.4 Size exclusion chromatography on Superdex™ 200 
 
Materials 
Running buffer 10 mM HEPES, 700 mM NaCl, pH 7.4 
  
Column Superdex™ 200 HR 10/30, prepack (Pharmacia) 
Total bead volumn: 24ml 
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Column material Superdex™ 200 High Resolution (Pharmacia) 
  
FPLC system Detector: L-4200 UV-VIS Detector (Merk-Hitach) 
 Pump: L-6200 Intelligent Pump (Merk-Hitach) 
 Collector: FC 203B Fraction Collector (GILSON) 
 Recorder: 2210 Recorder (LKB) 
  
Centrifuge Filter Amicon® Ultra-4 Centrifuge Filter Device (Millipore) 
 
Procedure 
1. Equilibrate the column with elution buffer with a flow rate of 0.5ml/min. 
2. Apply the protein sample to the column. For better chromatographical resolution, 
apply not more than 500 μl of every probe. 
3. Run the chromatography with a flow rate of 0.5ml/min. Collect 0.5 ml per fraction. 
Follow the elution profile with UV flow photometer, monitoring at wave length 280 
nm. 
4. Analyse the collected fractions with SDS-PAGE and select those containing protein in 
certain size. 
5. Concentrate fractions containing the purified target protein on Amican® Ultra-4 to the 
final concenration of about 1 mg/ml and store at -20℃. 
 
2.16.5 Reversal phase HPLC 
 
Materials 
Buffer A 0.1% Trifluoroacetic acid 
Buffer B Acetonitrile 
  
Column Vydac-214TP; C4; 10μM pore size; 0.46 x 25cm, analytical; 1 x 
25 cm, preparative 
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Detector: L-4200 UV-VIS Detector (Merk-Hitach) 
Pump: L-6200 Intelligent Pump (Merk-Hitach) 
Collector: FC 203B Fraction Collector (GILSON) 
HPLC system 
Recorder: LR 66920 Recorder (Pharmacia) 
 
Procedure 
1. Equilibrate the column with Buffer A. 
2. Apply protein solution to C4 column, equilibrated with buffer A. Apply not more 
than 20mg of protein to preparative column and 100ug to analytical column. 
3. Elute the protein with 0 -100% acetonitrile linear gradient, achieved through mixing 
with buffer B. Program flow rate for preparative column to 3 ml/min with fraction 
size 4.5ml, and respectively for analytical column to 0.7 ml/min with fraction size 
1ml. Follow the elution profile with UV flow photometer, monitoring at wave length 
280 nm. 
       Gradient: 
Time (min) % Acetonitrile
0 0 
5 25 
40 30 
50 100 
4. Collect the fractions of the peak and store at -80℃ for the lyophylization. 
 
2.17 Analysis of Protein-Protein interaction by BIAcore technology 
 
The kinetic and thermodynamic analysis of protein-protein interaction between CHL2 or 
its VWC domains and BMP-2 was performed in BIAcore™ 2000.  
BIAtechnology enables detection of biomolecules and monitoring of binding events 
between two or more molecules, in real time, without the use of labels. This technology 
relies on phenomenon of surface plasmon resonance (SPR) which occurs when surface 
plasmon waves are excited at a metal/liquid interface. The SPR phenomenon occurs in the 
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gold film at the tip of a sensor probe. White light passed into the optical fibre of the probe 
is totally internally reflected at the surface interfaces. Biomolecular binding events cause 
changes in the refractive index close to the surface and the wavelength of the reflected 
light intensity minimum shifts. By monitoring the output spectrum of the reflected light 
BIAcore probe is able to detect biomolecular binding occurring at the probe surface. 
During a binding analysis SPR changes occur as a solution is passed over the surface of a 
sensor chip. The sensor surface forms one wall of a flow cell. A sample containing the 
other interactant(s) is injected over this surface in a precisely controlled flow, light at a 
fixed wavelength, in a fan-shaped form, is directed at the sensor surface and biomolecular 
binding events are detected as changes in the particular angle where SPR creates 
extinction of light This change which reflects the progress of an interaction is measured 
continuously to form a sensorgram, which provides a complete record of the progress of 
association or dissociation of the interactants. 
The analyte binds to the surface-attached ligand during sample injection, resulting in 
increase in signal. At the end of the injection, the sample is replaced by a continuous flow 
of buffer and the decrease in signal now reflects dissociation of interactant from the 
surface-bound complex. Binding events cause changes in the refractive index at the 
surface layer, which are detected as changes in the SPR signal. In general, the 
refractive index change for a given change of mass concentration at the surface layer is 
practically the same for all proteins and peptides, and also similar for glycoprotein, lipids 
and nucleic acids. Resonance signal is measured in so called Refractive Units (RU) - a 
response of 1000 RU corresponds to a change in surface concentration of 1 ng/mm2. 
After the measurement cycle, the added regeneration buffer causes an immediate 
dissociation of non-covalently bound substances from the matrix without affecting 
binding activity of covalently linked immobilized binding partner. In this way the sensor 
chip is regenerated for new measurement cycle. 
 
2.17.1 Immobilizing of proteins through biotin-streptavidin coupling 
 
Materials 
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EDC 50 mM N-Ethyl-N'-(dimethylaminopropyl) carbodiimid 
NHS 200 mM N-hydroxysuccinimid 
HBS 10 mM Hepes pH 7.4,150 mM NaCl, 3.4 mM EDTA, 0.005% 
Surfactant P20 
Streptavidin solution 100 ug/ml Streptavidin in 10 mM NaOAc pH 4.5 
Regeneration buffer 100 mM HOAc, 1 M NaCl, pH 3.0 
 
Procedure 
Biotinylated BMP-2, mCHL2 or its VWC domains or Tsg immobilized on the dextran 
matrix of the sensor chip (CM5, BIAcore) by covalently conjugated with streptavidin. 
Immobilization was performed according to the recommendation of the supplier (BIAcore 
Handbook). For the immobilization biotinylated protein was applied at concentration of 
1-3 ug/ml. 
 
2.17.2 Measurement of binding of analytes 
 
Materials 
Buffer 10mM HEPES, pH 7.4; 500mM NaCl; 3,4mM EDTA, 0,05% P20 
System Biosensor BIAcore 2000TM (BIAcore) 
 
Procedure 
The sensorgram obtained on BIAcore™ 2000 could be characterized by the following 
three phases: 
1. Association of CHL2 or its WVC domains with immobilized interaction partner after 
injection. 
2. Equilibrium between processes of association and dissociation: a plateau on the 
sensorgram. 
3. Dissociation of CHL2 or its VWC domains upon switch on running buffer. 
Association and dissociation phases carry information about kinetic of binding, 
whereas the level of the plateau yields the thermodynamic affinity of binding. 
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Calculations of kinetic and thermodynamic constants are performed with 
BIAevaluation 2.0 program. 
4. For dissociation constants (KD) of <50 nM, kinetic constants (kon and koff) were 
evaluated. For KD values of >50 nM, dose-dependent equilibrium binding was 
evaluated. KD values or rate constants koff/kon were evaluated from one experiment 
determined for 6–9 different concentrations of the analytes. 
 
2.18 Biological activity in cell line 
Inhibition of BMP-2 induced Alkaline Phosphatase (ALP) activity by CHL2 or its VWC 
domains was assessed by ALP assay in C2C12 cell line. 
Materials 
75 cm2 culture flasks, 50 ml Falcon Tubes, Sterile pipette-syringe for Gilson, 
Multichannel pipette, 10 ml transfer pipette, 96-well plates sterile, 100 μl 
comptips for multipipette, 1.5 ml Eppicaps 
 
45g Glucose /100 ml H2O, PBS, 2 x trypsin in PES, PCS, CS, Penicillin/Strap, 
Glutamine 200 mM, DMEM medium 
 
Paranitrophenylphosphat (PNPP, store -20℃) (20 mg/ml H2O).  
freshly prepared C2C12 cells 
 
Alkaline lysis butter 1 0.1M Glycine pH9.6; I % Nonidet P40 substitute 
(Fluka); 1mM MgCl2; 1 mM ZnCl2 
Alkaline lysis butler 2 0.1 M Glycine pH9.6; 1 mM MgCl2 1 mM ZnCl2 
 
Procedure 
1. Remove medium from confluent cells. 
2. Trypsinize cells using 2 ml of 2 x trypsin for 5 min at RT. Stop trypsinization by 
adding 4 ml of 10% FCS-medium. 
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3. Spin down cells by 1200 rpm centrifugation for 2 min. Resuspend cells in 10 ml of 
10% FCS-medium and count cells. Then dilute cells to 1.5 x 105 cells/ml and add 100 
μl/well in 96-well plates (1.5 x 104 cell/well). 
4. Incubate for 24 h at 37℃ with 10% CO2. 
5. Suck out medium. Add 100 μl/well of 2% FCS-medium starting from second well. 
6. Dilute protein to 10 x concentration and 1:10 dilution in 2% FCS-medium. 
7. Add protein solution in first well and dilution until well11 and well 12 used as 
negative control. 
8. Incubate for 72 h at 37℃ /10% CO2. 
9. Suck out medium and wash with 100μl PBS. 
10. Add 100 μl alkaline lysis buffer 1/well and 1 h at RT shaking. 
11. Mix 10 ml alkaline lysis buffer 2 with 1ml PNPP and add 100 μl/well. 
12. Wait for colour reaction for 20-30 min and measure absorbance at 405nm in the 
ELISA reader. 
 
2.19 Crystallization of proteins 
 
2.19.1 Preparation of protein samples for crystallization 
 
The purified CHL2 or CHL2-VWC3 (1mg/ml, in 10 mM HEPES, 700 mM NaCl, pH 7.4) 
was mixed with BMP-2 (1mg/ml, in H2O) at molar ratio of 2.5 or 2.2:1 respectively on 
ice. The mixture was incubated for 30 min at 0℃. Then the sample was centrifuged at 
4000x g for 10 min at 4℃ to sediment precipitated proteins. The 2:1 of CHL2/BMP-2 or 
CHL2-VWC3/BMP-2 complex was purified by size exclusion chromatography on 
Superdex™ 200 column. At the last for the crystallization, the purified protein complex 
was concentrated to 8-11 mg/ml by Amicon® Ultra-4 Centrifuge Filter. 
 
2.19.2 Crystallization of proteins by vapour diffusion method 
 
Materials 
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Crystal research Kits (Hampton Research; Emerald BioSystems; QIAGEN; European 
Molecular Biology Laboratory, Hamburg); Baysilone paste (Roth); 96-well sitting drop 
plate; 24-well hanging drop plat; siliconized glass, circle cover slides, 22mm (Hampton) 
 
Procedure 
 
Sitting-drop technique  
The initial crystallization trials were performed 
by using crystal research Kits with Sitting-drop 
technique in 96-well plates. The sitting-drop 
vapor diffusion technique is a method for the 
crystallization of macromolecules. A sitting 
droplet composed of a mixture 1μl each of 
protein sample and reagent is placed in vapor 
equilibration with 100μl of reagent in reservoir. 
Typically the droplet contains a lower reagent 
concentration than the reservoir. To achieve 
equilibrium, water vapor leaves the droplet and 
eventually ends up in the reservoir. As water 
leaves the droplet, the sample undergoes an 
increase in relative supersaturation and forms 
crystal step by step. Both the sample and 
reagent increase in concentration as water 
leaves the droplet for the reservoir. At the last 
equilibration is reached when the reagent 
concentration in the drop is approximately same 
as that in the reservoir (Figure 2.2). 
 
Hanging-drop technique 
The fine screen experiments were set up with 24-well plates, siliconized glass cover and 
silicon grease. The hanging drop vapor diffusion technique is also a popular method for 
Figure 2.2: Sktch map showing process of vapor 
diffusion of sitting-drop technique. 
(Modification from Hampton Research Web site: 
http://www.hamptonresearch.com/support/pdf101/4.pdf )
Reagent
Figure 2.3: Sktch map showing process of vapor 
diffusion of hanging-drop technique. 
(Modification from Hampton Research Web site: 
http://www.hamptonresearch.com/support/pdf101/3.pdf) 
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the crystallization of macromolecules. A hanging droplet is prepared by mixing 1μl each 
of protein sample and reservoir reagent and placed in vapor equilibration with 500μl of 
reagent in reservoir. The principle of hanging-drop technique is same as sitting-drop 
technique. The hanging droplet has a lower reagent concentration than the reservoir. 
Water vapor leaves the droplet and ends up in the reservoir for achieving equilibrium. 
Equilibration is reached when the reagent concentration in the drop is approximately 
same as that in the reservoir (Figure 2.3). 
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3 Results 
 
3.1 Preparation of mCHL2 and its mutants in SF9 cells 
 
In this experiment, the wild type mouse CHL2 (mCHL2) was first expressed in SF9 cells 
for the further functional and structural analysis of mCHL2/BMP-2 interaction. The 
mCHL2 is a secreted glycosylated protein of 67 KDa. There are two potential 
glycosylation sites which reside at N89 and N180. To facilitate the crystallization of 
BMP-2/CHL2 complex, three mCHL2 mutants were constructed to prevent glycosylation. 
In two single mutants (mCHL2-N89Q, mCHL2-N180Q) each of the two glycosylation 
sites was mutated singly and in one double mutant (mCHL2-N89Q/N180Q) both 
glycosylation sites were simultaneously removed.  
 
3.1.1 Modification of pAcGP67-B/Th vector. 
 
pAcGP67-B/Th vector is a transfer plasmid for expression of His-tag proteins in SF9 cells. 
As the mCHL2 cDNA contains BamHI restriction endonuclease site which is the cloning 
site in the vector, we modified pAcGP67-B/Th to pAcGP67-B/Th/m by replacing BamHI 
site with StuI and XbaI sites. The mutation was generated by using a two-step PCR. The 
cDNA synthesized during the second step of the PCR contained the target mutation: 
BamHI site was replaced by StuI and XbaI sites (Figure 3.1, A). This mutant cDNA as an 
insert and the original pAcGP67-B/Th plasmid as a vector were respectively digested by 
EcoRV and BglII. The digested pAcGP67-B/Th vector was purified by Gel Extraction Kit 
and the amounts of insert and vector were roughly estimated by checking the bands in 
agarose gel. Finally the insert was ligated into vector (Figure 3.1, B). The recombinant 
plasmid DNA of pAcGP67-B/Th/m was transformed into competent E.coli MM294 and 
the positive clone were identified by checking the EcoRV/BglII digestion products of the 
DNA from different colonies. After sequence determination, the new pAcGP67-B/Th/m 
plasmid was used for the further experiments. 
 64
 
3.1.2 Cloning of mCHL2 and its mutants into pAcGP67-B/Th/m 
 
The cDNA of mCHL2 (Figure 3.2-1/-2) encoding the residues 1-401 of the mature 
mCHL2 was inserted into the transfer vector pAcGP67-B/Th/m between StuI and XbaI 
restriction sites (Figure 3.3). 
Then the plasmid carrying mCHL2 and mutant mCHL2 cDNA were used for 
transformation of competent E.coli MM294. The first selection of plasmid containing 
P1 and P4: External primer EXM-s and PAC-a 
P2 and P3: Mutational primer PAC-Ga and PAC-Gs (See table 2.1) 
 
Figure 3.1: A, Two-step PCR procedure. Two-step PCR was used to generate a mutational
cDNA which was synthesized during the second step of the PCR to gain the target mutation: 
BamHI was replaced by StuI and XbaI. The mutational cDNA was inserted into the 
pAcGP67-B/Th between EcoRV and BglII to form a new transfer vector pAcGP67-B/Th/m. B, 
Maps of Baculovirus transfer vector pAcGP67-B/Th and pAcGP67-B/Th/m.  
A 
B 
Two-step PCR:  
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Figure 3.2-1: The complete nucleotide and amino acid sequence of mCHL2. The colored boxes 
indicate the signal peptide and three VWC domains. The red letters are two potential 
N-glycosylation sites. 
: Signal peptide      : VWC1       : VWC2      : VWC3 
-1 -15 
-35 
-55 
-75 
-95 
-115
-135
-155
-175
-195
-215
-235
-255
-275
-295
-315
-335
-355
-375
-395
-401
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A :  Mature mCHL2 (Expressed in Sf9 insect cell with pAcGP67-B/Th/m vector, 401 
amino acids) 
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P L H C S Q P V M E P Q Q C C P R C V D P H V P S G L RV P L K S C Q L N E T T Y Q H G E I F S A Q E L F P
A R L S N Q C V L C S C I E G H T Y C G L M T C P E P S C P T T L P L P D S C C Q T C K D RT T E S S T E E
N LT Q L Q H G E R H S Q D P C S E R R G P S T PA P T S L S S P L G F I P R H F Q S V G M G S T T I K I I L
K E K H K K A C T H N G K T Y S H G E V W H P T V L S F G P M P C I L C T C I D G Y Q D C H RV T C P T
Q Y P C S Q P K K VA G K C C K I C P E D E A E D D H S E V I S T R C P K V P G Q F H V Y T L A S P S P D S
L H R F V L E H E A S D Q V E M Y I W K LV K G I Y H LV Q I K RV R K Q D F Q K E A Q N F R L LT G T H
E G Y W T V F L A Q T P E L K V TA S P D K V T K T L -
401
R P LV P R G S H H H H H H G A - -  
 
B: mCHL2-VWC1 (Expressed in E.coli with QKA vector, 78 amino acids) 
 
1 - R S R S G K V C L F G E K I Y T P G Q S W H P Y L E P Q G T I Y C V R C T C S E N G H V N C Y R L R C P
P L H C S Q P V M E P Q Q C C P R C V D P H V P S G -
78
 
 
C: mCHL2-VWC2 (Expressed in Sf9 insect cell with pAcGP67-B/Th/m vector, 99 
amino acids) 
 
71 - V D P H V P S G L RV P L K S C Q L N E T T Y Q H G E I F S A Q E L F PA R L S N Q C V L C S C I E G H
T Y C G L M T C P E P S C P T T L P L P D S C C Q T C K D RT T E S S T E E N LT Q L Q H G E -
16 9
 
 
D: mCHL2-VWC3 (Expressed in Sf9 insect cell with pAcGP67-B/Th/m vector, 99 
amino acids) 
 
203 - S V G M G S T T I K I I L K E K H K K A C T H N G K T Y S H G E V W H P T V L S F G P M P C I L C T C
I D G Y Q D C H RV T C P T Q Y P C S Q P K K VA G K C C K I C P E D E A E D D H S E V I S T R -
301
 
 
E: mCHL2-VWC3-Short (Expressed in E.coli with QKA vector, 74 amino acids) 
 
217 - E K H K K A C T H N G K T Y S H G E V W H P T V L S F G P M P C I L C T C I D G Y Q D C H RV T C P
T Q Y P C S Q P K K VA G K C C K I C P E D E A -
29 0
 
 
Figure 3.2-2: The amino acid sequence of mature mCHL2 (A) and its VWCs (B, C, D, E) 
expressed in this study. D and E are all VWC3, but have different numbers of residues in 
flanking sequences and expressed in different systems. Cysteines are highlighted in red. 
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MM294 was performed by plating on Ampicillin agar plate. Because the plasmid contains 
Ampicillin resistance gene, only bacterial cells carrying plasmid pAcGP67-B/Th/m-mCHL2 
or pAcGP67-B/Th/m-mutant mCHL2 or empty pAcGP67-B/Th/m would be able to form 
colonies. The later selection procedure was completed by analytical restriction digestion of 
the purified cDNA. The intact circular plasmid was digested with StuI and XbaI to confirm 
the presence of mCHL2 or mutant mCHL2 cDNA in the plasmid. The positive clones showed 
a band of 1203 bp after displaying the restriction digestion reaction on 1% agarose gel. The 
positive plasmid DNA was prepared and purified by DNA maxi preparation Kit (see 2.11.8) 
for sequencing. Sequence was verified to CHL2 wildtype and mutants. The plasmid DNA 
with correct sequence was used for storage and following co-transfection. The mutants of 
mCHL2 are shown below: 
 
3.1.3 Co-transfection of BaculoGold DNA and the transfer vectors into SF9 insect cells 
and amplification of the recombinant virus 
Mutants 
Mutant 1:  mCHL2-N89Q 
Mutant 2:  mCHL2-N180Q 
Mutant 3:  mCHL2-N89Q/N180Q 
Figure 3.3: Map of transfer vector pAcGP67-B/Th/m-mCHL2. The cDNA of mCHL2 is 
cloned into the transfer vector pAcGP67-B/Th/m between StuI and XbaI restriction sites  
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The first step necessarily to construct recombinant Baculoviruses was co-transfection of 
the transfer vector pAcGP67-B/Th/m containing mCHL2 or mCHL2 mutants cDNA and 
BaculoGold DNA into SF9 insect cells. BaculoGold DNA is a modified AcNPV 
Baculovirus DNA, which contains a lethal deletion and does not code for viable virus. 
Co-transfection of the BaculoGold DNA with a complementing Baculovirus Transfer 
Vector, such as pAcGP67-B, rescues the lethal deletion by homologous recombination. 
Since only the recombinant BaculoGold produces viable virus, a recombination frequency 
of 99 % is expected. To purify the stock of generated recombinant viruses during 
co-transfection, plaque purification was performed. Since each plaque represents a single 
virus, six individual plaques were randomly picked and used to generate clonal virus 
populations. Then the selected clonal virus populations were separately amplified twice. 
Finally a Western blot was performed with the virus supernatants to verify the protein 
production (Figure 3.4, 3.5, 3.6). In 23 of 24 tested supernatants expression of mCHL2 
protein was detected. The virus clone, which showed the largest amount of recombinant 
mCHL2 or mutants, was selected for further amplification. 
Two additional cycles of virus amplification were performed to produce a larger stock of 
recombinant virus with a high titer. Using a plaque assay the viral titer was determined to 
vary between 5 x 107 to 1 x 108 pfu/ml. An aliquot of the virus was stored at 4 oC for 
long-term storage and the rest was used to infect SF9 cells for expression of recombinant 
protein. 
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Wild type mCHL2 
 
Figure 3.4: Analysis of mCHL2 expression in SF9 cells. Virus medium infected with Baculovirus
containing mCHL2 cDNA was applied to western blot and detected by Anti-his tag antibody. C, 
Positive control (chordin VWC1-His-tag expressed in SF9 with Baculovirus transfer vector 
pAcGP67-B/Th); lines 1-6, examined recombinatant virus clones of wild type mCHL2. The 
theoretical molecule weight of mCHL2 is 46.84 KD. The glycosylated proteins run at about 50 KD.
C           1      2      3      4     5      6 
KD 
 
84— 
58— 
48— 
 
 
 
36.5— 
26.6— 
Figure 3.5: Analysis of the expression of mCHL2-N89Q (A) and mCHL2-N180Q (B) in SF9 
cells. Virus medium infected with Baculovirus containing mCHL2 mutants cDNA was applied 
to western blot and detected by Anti-his tag antibody. C, Positive control (wild type mCHL-2 
expressed in SF9 with Baculovirus transfer vector pAcGP67-B/Th/M); lines 1-6, examined 
recombinatant virus clones. The theoretical molecule weight of mCHL2-N89Q and 
mCHL2-N180Q are both 46.85 KD.  
A 
KD 
 
58— 
48— 
 
 
 
 
B
KD
58—
48—
1  2  3  4  5  6     C             1   2  3  4  5   6          C 
mCHL2-N89Q                          mCHL2-N180Q  
C    1     2     3    4    5    6      
mCHL2-N89Q/N180Q 
 
Figure 3.6: Analysis of mCHL2-N89Q/N180Q expression in SF9 cells.  Virus medium infected 
with Baculovirus containing mCHL2 double mutant cDNA was applied to western blot and 
detected by Anti-his tag antibody. C, Positive control (wild type mCHL-2 expressed in SF9 with 
Baculovirus transfer vector pAcGP67-B/Th/M); lines 1-6, examined recombinatant virus clones of 
mCHL2-N89Q/N180Q, The theoretical molecule weight of mCHL2-N89Q/N180Q is 46.87 KD. 
KD 
  
58— 
48— 
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3.1.4 Expression and purification of mCHL2 and its mutants 
 
Recombinant proteins were expressed in SF9 insect cells after infection with high titer 
virus stock. The infected cells were incubated in roller-bottle with 10% FCS SF9-medium 
for 4 days at 27 oC. Protein expression was performed in serum-containing insect culture 
medium. The presence of serum increased the cell viability and the amount of expressed 
protein. Since it did not interfere with the purification procedure, serum was kept in the 
expression medium. Under these conditions, the expression of recombinant mCHL2 and 
its mutants from SF9 cells yielded 0.7-2 mg protein per liter of SF9 cells (see below). The 
mature recombinant proteins could be purified from the infection supernatant, which was 
collected at the end of the incubation period. 
 
3.1.4.1 Purification of proteins by Ni-NTA chelating chromatography 
 
The Ni-NTA Purification System is designed for purification of 6xHis-tagged 
recombinant proteins expressed in bacteria, insect, and mammalian cells. The mCHL2 
and its mutants were expressed in SF9 cells with 6xHis-tag and thereby purified by 
Ni-NTA as a first step. After the expression, the culture supernatant was passed over the 
Ni-NTA chelating column and washed with wash-buffer to clean the column from 
non-specifically bound proteins. The specifically bound mCHL2 were eluted with 
elution-buffer (50 mM NaH2PO4, 300 mM NaCl, 300 mM Imidazol, pH 8.3). The protein 
amount and purity of the collected fractions were analyzed on SDS-PAGE (Figure 3.7, 
3.8). 
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3.1.4.2 Purification of proteins by cation exchange chromatography  
 
Since the pI of mCHL2 and its mutants are around 8.14, the proteins were applied to 
SP-sepharose at pH7.4. During this cation exchange chromatography, the acidic and 
Figure 3.8: Purification of mCHL2-N89Q (A) and mCHL2-N89Q/N180Q (B) by Ni-NAT 
chelating column. Lines 1, elution fraction 3, under reduced condition (R); Lines 2, elution 
fraction 3, under non-reduced condition (NR). M, marker of protein molecular weight.The 
mutants mCHL2 are indicated by arrow. 
KD
94 
67 
43 
30 
20 
14 M          1            2 
R           NR 
B 
M        1         2 
R            NR 
A 
KD 
94 
67 
43 
30 
 
20 
 
14 
M        1   2   3         4   5  6  
R                   NR  
Figure 3.7: Purification of wild type mCHL2 by Ni-NAT chelating column. Lines 1-3, elution 
fractions 2-4, under reduced condition (R); Lines 4-6, fraction 2-4, under non-reduced condition 
(NR). Wild type mCHL2 is indicated by arrow. M, marker of protein molecular weight. 
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neutral contaminating proteins could not bind to the column. Therefore the mCHL2 and 
its mutants could be effectively separated. The bound proteins were eluted with linear salt 
gradient from 0 M to 1 M NaCl. The protein amount and purity of the collected fractions 
were analyzed on SDS-PAGE (Figure 3.9, 3.10). 
 
Figure 3.9: Purification of wild type mCHL2 by SP-sepharose cation exchange 
chromatography. A, The elution chart of wild type mCHL2. The samples are applied to 
SP-sepharose column equilibrating with 20mM Tris, pH7.4. The target protein is eluted by 
linear NaCl concentration gradient. B, SDS-PAGE analysis of collected elution fractions 
(25-30) for wild type mCHL2. M, marker of protein molecular weight; FH, Flow through; R, 
under reduced condition; NR, under non-reduced condition. The mCHL2 is indicated by 
arrow. 
FH 
25 30
A B
M     25-30     25-30        FH 
R             NR              R 
KD
94
67
43
30
 
20
 
14
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3.1.4.3 Purification of proteins by BMP-2 affinity chromatography 
 
A column containing BMP-2-sepharose 4B gel was prepared and used for affinity 
chromatography. The protein solution after cation-exchange chromatography purification 
was passed over the BMP-2 affinity matrix and washed with wash buffer (10 mM HEPES, 
500 mM NaCl, pH 7.4) to clean the column from non-specifically bound proteins. The 
specifically bound wild type mCHL2 and its mutants were eluted with 4M MgCl2. The 
protein amount and purity of the collected fractions were analyzed on SDS-PAGE (Figure 
3.11). 
Figure 3.10: Purification of mCHL2 mutants by SP-sepharose cation exchange chromatography. 
A, The elution chart of mCHL2-N89Q/N180Q. The samples are applied to SP-sepharose column 
equilibrating with 20mM Tris, pH7.4. The target proteins are eluted by linear NaCl concentration 
gradient. The mCHL2-N89Q and mCHL2-N180Q are also purified by SP-sepharose cation
exchange chromatography with the same protocol as the mCHL2-N89Q/N180Q. After the 
purification, the two mutants can get similar elution charts to mCHL2-N89Q/N180Q. B, SDS-PAGE 
analysis of collected fractions for mCHL2-N89Q. C, SDS-PAGE analysis of collected elution
fractions for mCHL2-N89Q/N180Q.  M, marker of protein molecular weight; FH, Flow through;
R, under reduced condition; NR, under non-reduced condition. The mCHL2 mutans are indicated 
by arrows. 
24 
27 
22 
A 
FH 
23   27        23   27       FH 
M          R                    NR              R 
KD
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B
KD
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M  FH  22  23  24  27      23  24  27 
              R                           NR          
 74
 
 
3.1.4.4 Purification of proteins by size exclusion chromatography 
 
The protein solution which was purified by BMP-2 affinity chromatography was applied 
to SuperdexTM 200 column. The separated fractions were analyzed with SDS-PAGE on 
purity and presence of possible structure isomers (Figure 3.12, 3.13). Finally the pure 
fractions were stored in -20 oC for further experiments.  
After the purification of Ni-NTA affinity chromatography, cation exchange 
chromatography, BMP-2 affinity chromatography and size exclusion chromatography, the 
expression of recombinant mCHL2 and its double mutant (mCHL2-N89Q/N180Q) from 
SF9 cells respectively yielded 2-2.5mg and 0.7-0.9mg per liter of SF9 cell suspension. 
B
Figure 3.11: Purification of wild type mCHL2 by BMP-2 affinity chromatography. A, The 
elution chart of wild type mCHL2. The samples are applied to BMP-2 affinity column 
equilibrating with 10 mM HEPES, 500 mM NaCl, pH 7.4. The target proteins are eluted by 
4M MgCl2. B, SDS-PAGE analysis of collected fractions for wild type mCHL2. Line 3, 4, 
fraction 3 and 4; M, marker of protein molecular weight; R, under reduced condition; NR,
under non-reduced condition. FH, flow through. The mCHL2 is indicated by arrow. 
M       3    4        3    4 
R            NR 
KD
94
67
43
30
20
14
A 
Fraction 12 
Fraction 2
FH 
4M MgCL2 elution 
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3.2 Preparation of mCHL2-VWC1 in E.coli 
 
3.2.1 Cloning of mCHL2-VWC1 into QKA vector 
 
Figure 3.13: Purification of mCHL2-N89Q/N180Q by superdex 200 column. A, The elution chart 
of mCHL2-N89Q/N180Q. The sample is running in 10 mM HEPES, 700 mM NaCl, pH 7.4. B, 
SDS-PAGE analysis of collected fractions for mCHL2-N89Q/N180Q.  mCHL2-N89Q/N180Q is 
indicated by arrow. M, marker of protein molecular weight; NR, under non-reduced condition. 
27 
34
KD
94
67
43
30
20
M        27-34 
NR 
A B
Figure 3.12: Purification of wild type mCHL2 by superdex 200 column. A, The elution chart of wild 
type mCHL2. The sample is running in 10 mM HEPES, 700 mM NaCl, pH 7.4. B, SDS-PAGE 
analysis of collected fractions for wild type mCHL2. Line 24-32, fraction 24-32; Wild type mCHL2 is
indicated by arrow; M, marker of protein molecular weight; NR, under non-reduced condition. 
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A
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mCHL2-VWC1 cDNA encoding the amino acids 1-78 of the mature mCHL2 was ligated 
into the QKA expression vector between NcoI and BamHI restriction sites (Figure 3.14). 
The recombinant plasmid was transformed into competent E.coli MM294. Then the 
transformed cell suspension was plated separately to Kanamycin-plates which were 
incubated at 37 ℃ overnight to develop colonies of the transformed cells. Sequencing of 
plasmid DNA from positive colonies was confirmed the correct cDNA insert. 
 
3.2.2 Expression and purification of mCHL2-VWC1 
 
For the expression of mCHL2-VWC1, E.coli was cultivated at 37 ℃ until reaching early 
states of logarithmic growth phase with OD550 of 0.5-0.7 and then induced by 1mM IPTG 
for 4h. Under these conditions, the recombinant mCHL2-VWC1 was expressed as 
inclusion body in the cell cytoplasm. The induced and non-induced bacteria were 
analyzed by SDS-PAGE (Figure 3.15, A).  
The inclusion bodies were completely dissolved in 6M GuHCl for denaturation and 
purified by size-exclusion chromatography on Sephacryl S300. Then every fraction was 
analyzed by SDS-PAGE (Figure 3.15, B). Later the target fractions containing denatured 
mCHL2-VWC1 protein were concentrated to a final absorbency of 20 OD/ml and refolded 
by the renaturation protocol. 
Figure 3.14: Map of expression vector QKA-VWC1. The cDNA of mCHL2-VWC1 is 
cloned into the expression vector QKA between NcoI and BamHI restriction sites. 
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The refolded mCHL2-VWC1 was purified by cation exchange chromatography, BMP-2 
affinity chromatograph, size exclusion chromatography of Superdex 200 and then HPLC 
(Figure 3.16). The final purified mCHL2-VWC1 was analyzed by Mass Spectrometry 
(Figure 3.17). The mass result showed that the measured molecular weight of 8883.092 
corresponds to the expected calculated molecular weight of 8883.036. This method can 
yield about 900μg VWC1 proteins per 10g wet cells. 
Figure 3.15: A, An analytical SDS-PAGE illustrating steps of mCHL2-VWC1 expression. 1, 
overnight culture; 2, OD 0.5 culture; 3, induced culture by IPTG.  B, Purification of the denatured
mCHL2-VWC1 by size-exclusion chromatography on Sephacryl S300 with 6 M Guanidin HCl, 50 
mM NaOAC, 1 mM EDTA, pH 5.0. mCHL2-VWC1 is indicated by arrows. M, marker of 
molecular weight; R, under reduced condition 
KD
94
67
43
30
20
14
KD 
94 
67 
43 
30 
20 
14
M            1      2      3               M        1   2    3    4    5    6 
R                                          R 
A B
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Figure 3.17: ESI/FT-ICR Mass spectrometry analysis of mCHL2-VWC1. Signal with 
average relative mass of 8883.092 corresponds to the expected mCHL2-VWC1 
(calculated molecular weight is 8883.036) 
mCHL2-VWC1, 50ug/ml, After Deconvolution 
Figure 3.16: Purification of CHL2-VWC1 by HPLC. A, The elution chart of 
mCHL2-VWC1. The samples are applied to HPLC column equilibrating with 0.1% 
Trifluoroacetic acid. The target proteins are eluted at around 27% of acetonitrile. B, 
SDS-PAGE of the fractions 20 and 21 of HPLC. mCHL2-VWC1 is indicated by arrow. M, 
marker of molecular weight; NR, under non-reduced condition. 
A 
20 21
B
M             20    21 
             NR 
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3.3 Preparation of mCHL2-VWC2 in SF9 cells 
 
3.3.1 Cloning of mCHL2-VWC2 into pAcGP67-B/Th/m 
 
The cDNA of mCHL2-VWC2 encoding the amino acids 71-169 was inserted into the 
transfer vector pAcGP67-Bm between StuI and XbaI restriction sites (Figure 3.18). 
 
Then the plasmid carrying mCHL2-VWC2 was transformed into competent E.coli 
MM294, and first selected by plating transformation cell suspension on Ampicillin agar 
plate. The later selection procedure was performed by analytical restriction digestion. The 
intact circular plasmid was digested with StuI and XbaI to confirm the presence of 
mCHL2-VWC2 in the plasmid. The positive clones could show a band of 297 bp after the 
restriction digestion reaction visualized on 2% agarose gel. Then the positive plasmid 
DNA was prepared and purified by DNA maxi preparation Kit (see 2.11.8) for DNA 
Sequencing. The plasmid DNA with correct sequence was used for storage and the 
subsequent co-transfection. 
 
3.3.2 Co-transfection of BaculoGold DNA and the transfer vector into SF9 insect cells 
Figure 3.18: Map of transfer vector pAcGP67-B/Th/m-VWC2. The cDNA of 
mCHL2-VWC2 is cloned into the transfer vector pAcGP67-B/Th/m between StuI and 
XbaI restriction sites. 
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and amplification of the recombinant virus 
 
The same protocol as the pAcGP67-B/Th/m-mCHL2 was used for the co-transfection and 
the amplification of the recombinant virus of pAcGP67-B/Th/m-mCHL2-VWC2 (see 
3.1.3). A Western blot was performed with the virus supernatants to verify the protein 
production (Figure 3.19) 
 
 
3.3.3 Expression and purification of mCHL2-VWC2 
 
After the expression step, the culture supernatant was purified by the Ni-NTA affinity 
column. Next the protein was applied to size exclusion chromatography- Sephacryl S-100 
column. The protein purity of the collected fractions was analyzed on SDS-PAGE (Figure 
3.20). 
 
Figure 3.19: Analysis of mCHL2-VWC2 expression in SF9 cells.  Virus medium infected 
with Baculovirus containing mCHL2-VWC2 cDNA was applied to western blot and detected 
by Anti-his tag antibody. C, Positive control (wild type mCHL-2 expressed in SF9 with 
Baculovirus transfer vector pAcGP67-B/Th/m); lines 1-6, examined recombinatant virus 
clones of mCHL2-VWC2, molecule weight of the target protein is 10.89 KD. 
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3.4 Preparation of mCHL2-VWC3 and its mutants 
 
3.4.1 Preparation of mCHL2-VWC3 in SF9 cells 
 
The same protocol as the preparation of mCHL2-VWC2 (its cDNA encoding 203-301 
amino acids of mature mCHL2) in SF9 cells was used for the preparation of 
mCHL2-VWC3 (see 3.3) (Figures 3.21, 3.22). The protein purity of the collected 
fractions was analyzed on SDS-PAGE (Figure 3.20). 
 
Figure 3.20: A, SDS-PAGE showing mCHL2-VWC2 and mCHL2-VWC3 purified by Ni-NAT 
affinity chromatography. B, SDS-PAGE showing mCHL2-VWC2 and mCHL2-VWC3 purified 
by size exclusion chromatography. M, marker of protein molecular weight; mCHL2-VWC2 and 
mCHL2-VWC3 were indicated by arrows. R, under reduced condition; NR, under non-reduced 
condition. 
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3.4.2 Preparation of mCHL2-VWC3 and its mutants in E.coli 
 
3.4.2.1 Cloning of mCHL2-VWC3 and its mutants into QKA vector 
 
mCHL2-VWC3 cDNA encoding amino acids 218-290 of the mature mCHL2 and its 
mutants cDNA were ligated to QKA expression vector between NcoI and BamHI 
Figure 3.21: Map of transfer vector pAcGP67-B/Th/m-VWC3. The cDNA of 
mCHL2-VWC3 is cloned into the transfer vector pAcGP67-B/Th/m between StuI and 
XbaI restriction sites. 
Figure 3.22: Analysis of mCHL2-VWC3 expression in SF9 cells.  Virus medium infected with 
Baculovirus containing mCHL2-VWC3 cDNA was applied to western blot and detected by 
Anti-his tag antibody. C, Positive control (wild type mCHL-2 expressed in SF9 with 
Baculovirus transfer vector pAcGP67-B/Th/m); lines 1-6, examined recombinatant virus 
clones of mCHL2-VWC3, molecule weight of the target protein is 10.94 KD. 
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             mCHL2-VWC3 
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restriction sites (Figure 3.23). The nucleotide and amino acid sequence of mCHL2-VWC3 
and its mutants are shown in Figure 3.24. The recombinant plasmids carrying 
mCHL2-VWC3 and mutant mCHL2-VWC3 cDNA were transformed into competent 
E.coli MM294. Then the transformed cell suspension was plated separately to 
Kanamycin-plates. The plates were incubated at 37℃ overnight to develop colonies of the 
transformed cells. Because the plasmid contains Kanamycin resistance gene, only 
bacterial cells carrying plasmid QKA/mCHL2-VWC3 or QKA/mutant mCHL2-VWC3 or 
empty OKA would be able to form clonies. The later selection procedure was completed 
by analytical restriction digestion of the purified cDNA. The intact circular plasmid was 
digested with NcoI and BamHI to confirm the presence of mCHL2-VWC3 or mutant 
mCHL2-VWC3 cDNA in the plasmid. The positive clones showed a band of 222 bp after 
the restriction digestion reaction has been visualized on 2% agarose gel. The positive 
plasmid DNA was prepared and purified by DNA maxi preparation Kit (see 2.11.8) for 
DNA Sequencing. The plasmid DNA with correct sequence was used for storage and 
following expression. 
To generate the mutants of mCHL2-VWC3, an alignment of mCHL2-VWC3 and col IIA 
VWC domain was performed. In the NMR structure of col IIA VWC, some residues 
expose to the surface, which are likely involved in BMP binding. The residues of 
mCHL2-VWC3 which corresponde to these amino acids of col IIA VWC were chosen for 
mutagenesis. The mutants of mCHL2-VWC3 are shown below: 
 
Mutant 1: VWC3-K228D
Mutants 
Mutant 2: VWC3-H237D
Mutant 3: VWC3-P238R
Mutant 4: VWC3-V240D
Mutant 5: VWC3-S242A
Mutant 7: VWC3-G279D
Mutant 6: VWC3-G244A
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3.4.2.2 Expression and purification of mCHL2-VWC3 and its mutants 
 
a) Expression of proteins in E.coli 
 
For the expression of mCHL2-VWC3 and its mutants, E.coli was cultivated at 37℃ until 
 
VWC3-K228D; VWC3-H237D; VWC3-P238R; VWC3-V240D; 
VWC3-S242A; VWC3-G244A; VWC3-G279D  
 
Figure 3.24: The nucleotide and amino acid sequence of mCHL2-VWC3 (A) and its mutants 
(B). The mutated residues were encircled. The 10 cysteines are highlighted in red. 
B 
A 228
237 238       240      242      244
279 
Figure 3.23: Map of expression vector QKA-VWC3. The cDNA of mCHL2-VWC3 is 
cloned into the expression vector QKA between NcoI and BamHI restriction sites. 
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reaching early states of logarithmic growth phase with OD550 of 0.5-0.7 and then induced 
by 1mM IPTG for 4h. Under these conditions, the recombinant mCHL2-VWC3 and its 
mutants were expressed as inclusion body in the cell cytoplasm. The non-induced and 
induced VWC3 bacteria were analyzed by SDS-PAGE (Figure 3.25). 
 
 
b) Preparation of inclusion body of proteins 
 
The bacterial cells were resuspended with PMSFMETBSE −β  buffer and sonicated following the 
protocol (see 2.14.3). The sediment containning inclusion bodies, was washed with 
0.67M GuHCl for 30 min at RT. 
 
c) Denaturation and refolding of proteins 
 
The inclusion bodies were completely dissolved in 6 M GuHCl for denaturation and 
purified by size-exclusion chromatography on Sephacryl S300. Then every fraction was 
analyzed by SDS-PAGE (Figure 3.26). Later the target fractions containing denatured 
mCHL2-VWC3 or its mutant protein were concentrated to the final absorbency of 20 
OD/ml and refolded by diluting 100 times with the refolding buffer (see 2.14.4) and 
Figure 3.25: An analytical SDS-PAGE illustrating steps of mCHL2-VWC3 expression. 1, 
overnight culture; 2, OD 0.5 culture; 3, induced culture by IPTG.  M, marker of 
molecular weight. R, under reduced condition. mCHL2-VWC3 is indicated by arrow. 
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incubating for 7 days at 4 oC. 
 
 
d) Purification of proteins by cation exchange chromatography on SP-sepharose 
 
The refolded mCHL2-VWC3 and its mutants were first purified by cation exchange 
chromatograph. Since the pI of mCHL2-VWC3 and its mutants are around 8.12, the 
proteins could be applied to SP-sepharose at pH 7.4. During this cation exchange 
chromatography, the acidic and neutral contaminating proteins could not bind to the 
column. Therefore the mCHL2-VWC3 and its mutants could be effectively separated. The 
bound proteins were eluted with linear salt gradient from 0 M to 1 M NaCl. The protein 
purity of the collected fractions was analyzed on SDS-PAGE. The eluted proteins consist 
of monomer and multimers which appear as two unseparate peaks (Figure 3.27). The wild 
type mCHL2-VWC3 was further purified by BMP-2 affinity chromatography. The 
CHL2-VWC3 mutants were purified by HPLC directly. 
Figure 3.26: Purification of the denatured mCHL2-VWC3 by size-exclusion 
chromatography on Sephacryl S300 with 6 M Guanidin HCl, 50 mM NaOAC, 1 mM EDTA, 
pH 5.0. A, The elution chart of mCHL2-VWC3 on Sephacryl S300. B, SDS-PAGE analysis of 
collected fractions indicated by fraction numbers. The fractions 8 to 15 were combined for the 
further experiments. mCHL2-VWC3 is indicated by arrows. M, marker of molecular weight; 
R, under reduced condition. 
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e) Purification of mCHL2-VWC3 by BMP-2 affinity chromatography 
 
The protein solution after the purification of cation-exchange chromatography was passed 
over the affinity matrix and washed with wash buffer (10 mM HEPES, 500 mM NaCl, pH 
Figure 3.27: Purification of wild type mCHL2-VWC3 by SP-sepharose cation exchange 
chromatography. A, The elution chart of wild type mCHL2-VWC3. The samples are applied 
to SP-sepharose column equilibrating with 20mM Tris, pH7.4. The target protein is eluted 
by linear NaCl concentration gradient from 0-1 M. B, SDS-PAGE analysis of collected 
fractions for wild type mCHL2-VWC3. M, marker of molecular weight; FH, Flow through; 
R, under reduced condition; NR, under non-reduced condition. The fractions from 17 to 34 
were combined for the further purification. mCHL2-VWC3 is indicated by arrows. 
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Figure 3.28: The elution chart of the purification of wild type mCHL2-VWC3 by BMP2 affinity 
chromatography. The samples are applied to BMP2 affinity column equilibrating with 10 mM 
HEPES, 500 mM NaCl, pH 7.4. The target proteins are eluted by 4M MgCl2. FH: flow through. 
Fraction 2
Fraction 12
FH 
4M MgCL2 elution
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7.4) to clean the column from non-specifically bound proteins. The specifically bound wild 
type mCHL2-VWC3 was eluted with 4M MgCl2 (Figure 3.28).  
 
f) Purification of proteins by size exclusion chromatography 
 
The protein solution which was purified by BMP-2 affinity chromatography was applied 
to SuperdexTM 200 column. The separated fractions were analyzed with SDS-PAGE on 
purity and presence of possible structure isomers (Figure 3.29). Finally the proteins were 
purified by HPLC. 
 
 
g) Purification of proteins by HPLC 
 
The protein purification was accomplished by reversed phase HPLC. Based on hydrophobic 
interactions, the protein bound to the chromatography matrix and the elution with increasing 
concentration of acetonitrile was performed. The mCHL2-VWC3 and its mutants were eluted 
at around 27% of acetonitrile. The collected fractions were analyzed by SDS-PAGE (Figure 
3.30). The highly purified proteins were divided into aliquots, lyophilized and stored at -20 oC 
for following mass spectrometry analysis. This method can yield about 1.5-2.2 mg CR3 
Figure 3.29: Purification of wild type mCHL2-VWC3 by size exclusion chromatography on 
superdex 200 column. A, The elution chart of mCHL2-VWC3. The sample is running in 10 
mM HEPES, 700 mM NaCl, pH 7.4. B, SDS-PAGE analysis of collected fractions from 33 to 
40 of wild type mCHL2-VWC3. The fractions from 33 to 40 were collected for further
experiments. M, marker of molecular weight; R, under reduced condition; NR, under 
non-reduced condition. Wild type mCHL2-VWC3 was indicated by arrow. 
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proteins per 10g wet cells. 
The mass spectrometry showed the measured molecular weight of 8360.776 for wild type 
VWC3 corresponds to the expected calculated molecular weight of 8360.750 (Figure 3.31). 
Figure 3.30: Purification of mCHL2-VWC3 by HPLC. A, The elution chart of 
mCHL2-VWC3. The samples are applied to HPLC column equilibrating with 0.1%
Trifluoroacetic acid. The target proteins are eluted at around 27% of acetonitrile. B, 
SDS-PAGE of the fractions 20 and 21 of HPLC. mCHL2-VWC3 is indicated by arrow. M, 
marker of molecular weight; NR, under non-reduced condition. 
M         20   21 
         NR 
mCHL2-VWC3, 50ug/ml, After Deconvolution 
Figure 3.31: ESI/FT-ICR Mass spectrometry analysis of mCHL2-VWC3. Signal with average 
relative mass of 8360.776 corresponds to the expected mCHL2-VWC3 (calculated molecular
weight is 8360.750) 
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3.5 Functional analysis of mCHL2 and its VWC domains 
 
3.5.1 Binding of mCHL2 and its VWC domains to BMPs 
 
The binding affinities of mCHL2 and its VWC domains to BMPs were analyzed by 
BIAcore technology with immobilized BMPs and mCHL2 respectively (Figure 3.32; 
Table 3.5, 3.6). mCHL2 bound to immobilized BMP-2 with a KD of 10 nM, and BMP-2 
bound to immobilized mCHL2 with an affinity of 1nM (Figure 3.32).These affinities are 
similar to those of BMP-2 for its high affinity type I receptor (Kirsch et al., 2000a; 
Keller et al., 2004). BMP-7 bound to immobilized mCHL2 with about 20 times lower 
affinity than BMP-2. GDF-5 bound to immobilized mCHL2 with lower affinity than 
BMP-2 and BMP-7.  
mCHL2 contains three VWC domains. We found that mCHL2-VWC1 and 
mCHL2-VWC3 bound to BMP-2, BMP-7 and GDF-5, but mCHL2-VWC2 did not (Table 
3.5, 3.6). Compared with full-length mCHL2, mCHL2-VWC1 and mCHL2-VWC3 
domains bound to immobilized BMP-2 with about 100 and 20 times lower affinity 
separately. The results indicate that the high affinity of mCHL2 to BMP-2 results from the 
cooperative binding of these two VWC domains. mCHL2-VWC1 and mCHL2-VWC3 
bound to BMP-7 with similar or slightly lower affinity as full-length mCHL2. 
mCHL2-VWC1 seems to account for most of the binding affinity for GDF-5 in the 
full-length mCHL2. Here again, the different binding affinities suggest that the single 
VWC domain has some selectivity for various BMP/GDF proteins. 
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Figure 3.32: BIAcore analysis of mCHL2/VWCs and BMP-2 interaction A1-A3, overlay of 
sensograms showing the binding of BMP-2 to the immobilized full-length mCHL2, mCHL2-VWC1 or 
mCHL2-VWC3. BMP-2 at different concentrations was applied. B1-B3, overlay of sensograms 
showing the binding of full-length mCHL2, mCHL2-VWC1 or mCHL2-VWC3 to the immobilized 
BMP-2. Full-length mCHL2, mCHL2-VWC1 or mCHL2-VWC3 at different concentrations were 
applied.  
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 Table 3.5: Binding analysis of BMPs and immobilized mCHL2/VWCs proteins (BIAcore) 
 
mCHL2 
Full-length VWC1 VWC2 VWC3  
Apparent KD (nM) 
BMP-2 1.2 130 NB 20 
BMP-7 21 32 NB 72 
GDF5 44 70 NB >1000 
NB, No binding. 
 
Table 3.6: Binding analysis of mCHL2/VWCs proteins and immobilized BMP-2 (BIAcore) 
 
BMP-2  
mCHL2 
Apparent KD (nM) 
Full-length 10 
VWC1 2200 
VWC2 NB 
VWC3 300 
NB, No binding. 
 
3.5.2 Binding epitopes of BMP-2 for mCHL2  
  
A collection of BMP-2 mutants which were mutated in the wrist and knuckle epitopes 
was used to delimit binding epitopes of BMP-2 for mCHL2. The decreases of the binding 
affinities between BMP-2 mutants and immobilized mCHL2 and its VWC domains 
indicate the influences of the amino acid substitutions in the wrist and knuckle epitopes for 
binding. According to the structure of the ternary complex of BMP-2/BMPR-IA/ActR-IIB 
(Weber et al., 2007), seven variants mutated in the wrist epitopes and eight variants 
mutated in the knuckle epitopes (Figure 3.33, A) in which single residues were substituted 
by alanine, charged residue or proline (Kirsch et al., 2000b; Keller et al., 2004), were 
selected for analyzing the interaction with mCHL2 and its VWC domains by Biacore. The 
mutants F49A, P50A, L51P, A52R, M106A, D53P, and S69R exhibited a reduced affinity 
for type I receptors. The mutants A34D, H39D, S88P, L90A, V98P, L100P, L100K and 
L100K/N102D bound type II receptors with reduced affinities (Kirsch et al., 2000b; 
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Keller et al., 2004; Zhang et al., 2007). mCHL2 bound many of the tested wrist and 
knuckle epitopes mutants with reduced binding affinity (Figure 3.33, B). The change of 
the affinity for the wrist epitope mutants was mild and for the knuckle epitopes mutants 
were relatively stronger. The results clearly indicate that mCHL2 binds to both the 
knuckle and wrist epitopes of BMP-2.  
The binding of BMP-2 mutants for mCHL2-VWC1/-VWC3 was also measured (Figure 
3.33, B). Almost all tested knuckle epitope mutants bound to mCHL2-VWC1 with 
significantly reduced binding affinity except mutant S88P. However, there was no 
difference of the binding affinities between wild type BMP-2 and the tested wrist epitope 
mutants to mCHL2-VWC1. In contrast, only wrist epitope mutants exhibited remarkable 
reduced binding affinity for mCHL2-VWC3 except mutant L51P. Together, the results 
indicated that the binding epitopes of BMP-2 for mCHL2 correspond with two different 
BMP-2 sites: the residues in the knuckle epitopes are involved in mCHL2-VWC1 binding 
and the residues in the wrist epitopes in binding to mCHL2-VWC3.  
Moreover, the decreases of the affinities of the variants to full-length mCHL2 were lower 
than those to the VWC1 or VWC3 domain. This might be due to the compensating effects 
of two cooperative VWC domains in full-length CHL2 molecule (Figure 3.33, B). 
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B 
mCHL2 
Full-length  VWC1 VWC3 Variants Epitope 
KD (nM) V/W KD (nM) V/W KD (nM) V/W 
BMP-2-Wild type   1.2 1.0 130 1.0 20 1.0 
BMP-2-F49A wrist 3.2 2.7 100 0.8 160 7.9 
BMP-2-P50A wrist 2.3 1.9 75 0.6 70 3.5 
BMP-2-L51P wrist 1.8 1.5 120 0.9 15 0.8 
BMP-2-A52R wrist 3.3 2.8 110 0.9 77 3.9 
BMP-2-D53P wrist ND - ND - 60 3.0 
BMP-2-S69R wrist 4.5 3.4 65 0.5 98 4.9 
BMP-2-M106A wrist 5.4 4.5 100 0.8 960 48 
        
BMP-2-A34D knuckle 10 8.3 28500 219 11 0.6 
BMP-2-H39D knuckle 1.8 1.5 280 2.1 15 0.8 
BMP-2-S88P knuckle 2.3 1.9 100 0.8 21 1.0 
BMP-2-L90A knuckle 11 9.2 4300 33 17 0.9 
BMP-2-V98P knuckle 6.2 5.2 1800 14 33 1.7 
BMP-2-L100P knuckle 3.6 3.0 1400 11 29 1.5 
BMP-2-L100K knuckle 4.3 3.6 700 5.4 28 1.4 
L100K/N102D knuckle 4.3 3.6 1300 9.8 37 1.9 
ND, Not done;  V/W, Ratio of KD (Variant/Wild type) 
Ratio of KD (Variant / Wild type) 
 
 
3.5.3 Binding mode of mCHL2 and BMP-2 
 
Previous study showed that binding affinities of BMP-2 for receptors are two orders of 
magnitude different when binding is measured by Biacore with immobilized ectodomain 
or with immobilized ligand, respectively (Kirsch et al., 2000b; Sebald et al., 2004). This 
difference has been explained by the assumption that the solute BMP-2 dimer binds 
simultaneously to two immobilized receptors on the chip (1:2 interaction), which results 
in an enhanced affinity, whereas the separate ectodomains bind immobilized BMP-2 in a 
Figure 3.33: Mutational analysis of BMP2 interaction with mCHL2 and its VWC domains  
A, Mutants in the wrist (Blue) and knuckle (Red) epitopes of BMP-2, which were selected for
analysis. The small ribbon model presents a view of BMP-2 along the 2-fold axis and shows 
the location of the wrist and knuckle epitopes. B, The binding affinities of wild-type and 
mutant BMP-2 for immobilized full-length mCHL2 and its VWC domains. Relative affinities 
(Ratio of KD) showing the influence of the mutations on binding. Values of relative KD are 
classified into six categories according to the colour code shown at the bottom of the table. 
 95
1:1 interaction, which results in a low affinity. Similarly the affinity of solute mCHL2 to 
immobilized BMP-2 was about 10-fold lower than that of solute BMP-2 to immobilized 
mCHL2 (Figure 3.33 and Table 3.5). Therefore, the binding of mCHL2 to BMP-2 may 
also follow the rule of BMP/ receptors interaction. In this case, two mCHL2 molecules 
bind to BMP-2 dimer in a 2:1 interaction. As two wrist and two knuckle epitopes exist in 
the BMP-2 dimer, this assumption of binding mode also fit to the result that VWC1 and 
VWC3 of mCHL2 bound respectively to the knuckle and wrist epitopes of BMP-2. 
The 2:1 stoichiometry of the mCHL2/BMP-2 complex is further confirmed by the 
analysis of gel-filtration chromatography and SDS-PAGE. The free mCHL2, BMP-2 and 
mixtures of BMP-2 and mCHL2 in different molar ratios were chromatographed on a 
Superdex 200 HR 10/30 column. When a 2.5:1 mixture of mCHL2 and BMP-2 was 
chromatographed, a major peak with an apparent molecular weight of 140 kDa was 
separated from a minor peak corresponding to the excess mCHL2 (Figure 3.34, A, c). 
When a 2:1 mixture of mCHL2 and BMP-2 was chromatographed, the whole protein was 
eluted as a single peak of 140 kDa (Figure 3.34, A, d). The apparent molecular weight of 
140 kDa agrees with the calculated molecular weight of 138 kDa for a 2:1 complex of 
mCHL2 and BMP-2. When a 1:1 mixture of mCHL2 and BMP-2 was chromatographed, 
the mixture was eluted with a major peak (140 kDa) and a second slight shoulder (Figure 
3.34, A, e). The main peak with an apparent molecular weight of 140 kDa matches the 
molecular weight of the 2:1 complex. But the apparent molecular weight of 80 kDa of the 
second shoulder observed only after separation of the 1:1 mixture is similar to the 
molecular weight of a 1:1 complex (80 kDa). Probably, the surplus of free BMP-2 
precipitated under this condition and was not recovered.  
Finally the quantitative protein composition of the chromatographed fractions was 
determined by SDS-PAGE analysis and subsequent Integrated Density (ID) analysis of 
the Coomassie stained proteins by the software of Scion Image (Figure 3.34, B). On the 
same gel, 2:1 and 1:1 mixtures of mCHL2 and BMP-2 were analyzed as standard. PAGE 
of the gel filtration fractions of the 2.5:1 CHL2/BMP-2 mixture revealed the complex 
formation by co-elution of mCHL2 and BMP-2 from fractions 22 to 26 (Figure 3.34, A, c). 
The ratio of the ID of the mCHL2 band relative to the BMP-2 band clearly showed that 
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the complex corresponded to the 2:1 complex, because the ratio of the protein bands in 
fractions of 24 and 25, which were the peak fractions, were very close to the standard 
ratio measured for the 2:1 molar ratio of mCHL2 and BMP-2 (Figure 3.34, B, c1, c2), but 
clearly different from the ratio of 1:1 molar ratio. The composition of the major peak in 
Figure 3.34, A, e also corresponded to a 2:1 complex (Figure 3.34, B, e1, e2). The 
quantitative analysis for the second peak (shoulder) was difficult because the two peaks in 
Figure 3.34 (A, e) displayed no baseline separation.  
According to the results of BIAcore and chromatography above, we can conclude that 
mCHL2 binds to BMP-2 with a 2:1 stoichiometry. 
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Figure 3.34: Stoichiometry of mCHL2/BMP-2 assembly.  A, Chromatographs of the gel filtration 
runs with A280 on the y-axis and elution volume Ve on the x-axis. a: mCHL2; b: BMP-2; c: 2.5:1 
mixture of mCHL2 and BMP-2; d: 2:1 mixture of mCHL2 and BMP-2; e: 1:1 mixture of mCHL2 and 
BMP-2. Protein samples were run at a flow rate of 0.5 ml/min on a Superdex 200 HR 10/30 column in 
10 mM HEPES, pH 7.4, 700 mM NaCl. B, c1, e1: SDS-PAGE of the fractions of 2.5:1 or 1:1 mixture 
of mCHL2/BMP-2 from gel filtration chromatography under non-reducing condition; c2, e2: ID 
analysis of the fractions of 2.5:1 or 1:1 mixture. ID: Integrated Density, which is calculated by the 
software Scion Image to analyze the quantities of Coomassie stained proteins. mCHL2:BMP-2 
standard: Standard mixtures of mCHL2/BMP-2 at a 2:1 and 1:1 molar ratios. Ratio of ID: The ratio of 
the ID of the CHL2 band relative to the BMP-2 band (ID mCHL2/ID BMP-2). PM, protein marker. 
 
c1 PMB
kDa
94 
67 
43 
30 
20 
24 25 29 30 2:1 2:1 1:1 1:1 
Fractions     mCHL2:BMP-2 standard 
e1 
kDa
94 
67 
43 
30 
20 
24 25 29 30 2:1 2:1 1:1 1:1 
Fractions     mCHL2:BMP-2 standard 
c: 2.5:1 mixture 
of mCHL2:BMP-2 
d: 2:1 mixture of 
mCHL2:BMP-2 
e: 1:1 mixture of 
mCHL2:BMP-2 
V (ml) e 
0   2.5   5  7.5  10  12.5  15  17.5  20  22.5  25 
a: mCHL2 
   130 66 43 13.7  kDa 
b: BMP-2 
A 
A280 nm 
0.05 OD 
24 
25 
29
30
22 
mCHL2:BMP-2 (2.5:1) 
Fractions 
mCHL2:BMP-2 Standard 
(mol/mol) ID 
24 25 29 30 2:1 2:1 1:1 1:1 
CHL2 51.64 65.76 54.43 36.41 73.37 69.69 36.33 36.26
BMP2 15.75 20.47 - - 23.22 22.17 15.17 15.06
Ratio of ID 3.28 3.21 - - 3.16 3.14 2.39 2.41
ID: Integrated Density
c2
mCHL2:BMP-2 (1:1) 
Fractions 
mCHL2:BMP-2 Standard 
(mol/mol) ID 
24 25 29 30 2:1 2:1 1:1 1:1 
mCHL2 64.27 53.38 42.53 32.24 53.92 59.26 36.52 38.12
BMP-2 18.36 15.21 2.27 1.38 15.72 16.93 14.32 14.66
Ratio of ID 3.50 3.51 - - 3.43 3.50 2.55 2.60
ID: Integrated Density
e2
24 
25 
29
30
 98
3.5.4 Competition of mCHL2/VWCs with receptors for BMP-2 binding 
 
It has been shown that mCHL2 inhibited BMP activity in a competitive manner in vitro 
(Nakayama et al., 2004). Here we investigated whether mCHL2 inhibit binding of BMP-2 
to type I or type II receptors by Biacore methodology. As shown in Figure 3.35, 100nM of 
mCHL2 prevented completely the binding of 50nM BMP-2 to immobilized BMPR-IA or 
ActR-IIB. These results demonstrated that mCHL2 could inhibit the binding of BMP-2 to 
both type I and type II receptors. 
The knuckle epitope binding protein mCHL2-VWC1 displayed no inhibition on 
BMP-2/BMPR-IA interaction even at very high concentration, and could inhibit the 
BMP-2/ActR-IIB binding by 50% at this concentration (Figure 3.35, 3). The wrist epitope 
binding protein mCHL2-VWC3 inhibited the binding of BMP-2 to BMPR-IA at high 
concentration (Figure 3.35, 2), but the mixture of BMP-2 and mCHL2-VWC3 showed an 
increased response (resonance unit, RU) to ActR-IIB, compared to BMP-2 alone, 
probably due to the increased mass of the stable BMP-2/mCHL2-VWC3 complex in 
which the binding site for type II receptor is not occupied (Figure 3.35, B, 2). These results 
suggested that BMP-2 could simultaneously bind mCHL2-VWC3 and type II receptor. 
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3.5.5 Biological activity in cell lines 
 
The inhibitory effect of mCHL2 proteins on BMP signaling was assessed by measuring the 
BMP-2 induced alkaline phosphatase (ALP) activity in C2C12 cells. mCHL2 inhibited 10 
nM BMP-2 induced ALP activity in a dose-dependent manner with a IC50 of 9 nM. In 
contrast, the single domain of mCHL2-VWC1 and mCHL2-VWC3 showed no inhibitory 
activity up to a concentration of 1 μM (Figure 3.36).  
In previous experiments the mutant BMP-2-L51P has been generated (Keller et al., 2004). 
This mutant does not bind BMPR-IA but binds to type II receptors normally. It does not 
induce measurable ALP activity in C2C12 cells and has no dominant-negative inhibitory 
effect. As the L51P mutant binds to mCHL2 normally (Figure 3.33, B), it can release 
Figure 3.35: Inhibition of the binding of BMP2-type I or -type II receptor by mCHL2 and its VWC
domains in Biacore.  BMPR-IA (A) and ActR-IIB (B) were immobilized on the chip surface.
50nM BMP-2 plus 100nM CHL2 (1), 3000nM CHL2-VWC3 (2), 4000nM CHL2-VWC1 (3) and 
50nM BMP-2 alone (4), were injected over the chip surface. C, summary of the results in A and B.
+++: Binding was completely prevented; ++: Binding was blocked by 80-90%; +/-: binding was 
blocked by 50%. -: No inhibition; --: Increased resonance unit was obtained. 
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inhibition of BMP-2-induced ALP activity by mCHL2 in a dose-dependent manner 
(Figure 3.37). Now, five double or triple mutants of BMP-2 were generated, in which the 
knuckle epitope mutants A34D, L90A, V98P, L100P and L100K/N102D were introduced 
in the background of the L51P mutation. These mutants showed an obvious reduced 
affinity for BMPR-IA, decreased affinities for BMPR-II, ActR-II, ActR-IIB, normal or 
decreased affinities for mCHL2 in Biacore measurement as to expect from the property of 
the single mutants. The inhibition of BMP-2 activity by mCHL2 could be partially 
relieved to different extents by L51P/L100P, L51P/V98P, L51P/L90A, L51P/A34D and 
L51P/L100K/ N102D (PKD) (Figure 3.37). The biological activity of the mutants (i.e., 
release of CHL2 inhibition) correlates with their binding affinities to mCHL2 (See Figure 
3.33, B).  
 
Figure 3.36: Inhibitory properties of mCHL2 and its VWC domains. Inhibition of the 10nM 
BMP2-induced alkaline phosphatase (ALP) activity by increasing doses of mCHL2, 
mCHL2-VWC1 and mCHL2-VWC3 was analyzed in serum-starved C2C12 cells. 
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3.5.6 Analysis of mCHL2-VWC3 determinants for BMP-2 binding 
 
Studies have shown that VWC domain is a versatile binding module. Most of the BMP 
binding VWC domains bind mainly the knuckle epitope of BMP-2. So far, only the 
VWC3 of mCHL2 is found to bind the BMP wrist epitope for type I receptor (Figure 3.35 
and Zhang et al., 2007). To further characterize the binding properties of VWC3 domain, 
we conducted mutational analysis for this domain. Seven mutants of VWC3 were 
randomly generated (Figure 3.24) namely mutants VWC3-K228D, VWC3-H237D, 
VWC3-P238R, VWC3-V240D, VWC3-S242A, VWC3-G244A and VWC3-G279D. Four 
of the seven mutants VWC3-H237D, VWC3-P238R, VWC3-V240D, and VWC3-G244A 
showed decreased binding affinities for BMP-2 compared to wild type VWC3. 
Remarkably, the VWC3-P238R exhibited a 130-fold lower affinity (Table 3.7). These 
results indicated that these four amino acids contribute strongly to the binding of VWC3 
Figure 3.37: Release of mCHL2 inhibited BMP-2 acivity by BMP-2 mutants. Induction of 
ALP by 10 nM BMP-2 in C2C12 cells was inhibited to 10% by 50 nM mCHL2. L51P and 
the compound mutants by themselves do not induce ALP activity. The release of 
mCHL2-inhibited BMP-2 activity was determined at the indicated mutant concentrations. 
PKD, L51P/L100K/N102D-BMP-2. 
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to BMP-2 and might be the determinants of VWC3 for BMP-2. 
 
 
3.5.7 Binding of mCHL2/VWCs to Tsg  
 
It is known that Chordin binds simultaneously to BMP4 and Tsg, and the formation and 
dissociation of Chordin/Tsg/BMP complex correspond to the pro-and anti-BMP activity 
of Chordin and Tsg (De Robertis and Kuroda, 2004 ). Studies also showed that the 
pro-BMP activity of Tsg is independent of BMP binding but is specific for Chordin-like 
protein. Therefore, Tsg might bind other Chordin-like proteins and exert its pro-BMP 
activity independent of Chordin (Oelgeschlager et al., 2003). To discover more 
Tsg-binding Chordin-like proteins, we analyzed the possible interaction between mCHL2 
and Tsg. We found that mCHL2 bound Tsg with high affinity, and the two BMP-binding 
VWC domain of mCHL2, VWC1 and VWC3, bound Tsg with 20-25 times lower affinity 
compared to full-length mCHL2 (Figure 3.38; Table 3.8). These results identify mCHL2 
as a novel Tsg binding partner and show that the VWC1 and VWC3 domain of mCHL2 
cooperatively generate a high binding affinity for Tsg. Furthermore, a stable 
Tsg/mCHL2/BMP-2 ternary complex could be isolated by gel-filtration chromatography 
(Figure 3.39, A). Biological assays showed that Tsg and mCHL2 synergistically inhibit 
Table 3.7: Binding affinity of CHL2-VWC3 mutants for immobilized BMP-2 
 
 BMP-2 
 KD (nM) V/W 
VWC3-wild type 300 1.0 
VWC3-K228D 280 0.9 
VWC3-H237D 12000 40 
VWC3-P238R 40000 130 
VWC3-V240D 9600 32 
VWC3-S242A 320 1.1 
VWC3-G244A 5300 18 
VWC3-G279D 410 1.4 
V/W, Ratio of KD (Variant/Wild type) 
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BMP-2-induced ALP activity (Figure 3.39, B). In summary, mCHL2 binds strongly to Tsg 
and forms a ternary complex with Tsg and BMP-2. This complex makes mCHL2 a better 
BMP-2 antagonist. 
Figure 3.38: BIAcore analysis of mCHL2/VWCs and Tsg interaction A1-A3, overlay of sensograms showing 
the binding of Tsg to the immobilized full-length mCHL2, mCHL2-VWC1 and mCHL2-VWC3. Tsg at 
different concentrations were applied. B1-B3, overlay of sensograms showing the binding of full-length 
mCHL2, mCHL2-VWC1 and mCHL2-VWC3 to the immobilized Tsg. Full-length mCHL2, mCHL2-VWC1 
and mCHL2-VWC3 at different concentrations were applied respectively. 
A1 
A2 
A3 
B1
B2
B3
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Table 3.8: Binding analysis of Tsg for mCHL2/VWCs (BIAcore) 
 mCHL2 
 Full-length VWC1 VWC2 VWC3 
 Apparent KD (nM) 
Tsga 13 330 NB 280 
Tsgb 24 870 NB 180 
a: immobilized; b: perfused; NB, No binding. 
 
Figure 3.39: Formation of the ternary complex of BMP-2/mCHL2/Tsg and synergistic effect 
of Tsg and CHL2 for inhibition of BMP-2 activity. A, Free BMP-2, mCHL2, Tsg, binary and 
ternary complexes of BMP-2/mCHL2 and BMP-2/mCHL2/Tsg were chromatographed on a 
Superdex 200 HR 10/30 gel-filtration column. The ternary complex of BMP-2/mCHL2/Tsg 
was analyzed by SDS-PAGE under the non-reducing condition. B, Inhibition of BMP-2 
activity (10 nM BMP-2) in serum starved C2C12 cells by different doses of Tsg, mCHL2 or 
Tsg plus mCHL2 was determined by analysis of the induced ALP activity. 
B 
A 
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3.6 Protein complexes formation and crystallizations of the complexes 
 
3.6.1 Crystallization of mCHL2/BMP-2 complex  
 
The purified wildtype mCHL2 was mixed with BMP-2 at a molar ratio of 2.5:1 on ice. 
The mCHL2/BMP-2 complex was isolated by size exclusion chromatography on 
Superdex™ 200 column. The fractions (22-26) containing the two components of the 
complex were pooled (Figure 3.40). The complex was concentrated to 8-11 mg/ml and 
submitted to crystallization. 
 
 
Figure 3.41: Initial screen of crystallization of mCHL2/BMP-2 complex. A, Single 
crystals growing in 0.1M Tris, pH 8.5, 25% w/v PEG3350; B, Needle crystals growing 
in 0.1MTris, pH 8.5, 25% tert-Butanol. The arrows indicate the crystals. 
A B
Figure 3.40: A, Chromatographs of the gel filtration on Superdex 200 for 2.5:1 mixture of mCHL2 
and BMP-2; B, SDS-PAGE of the fractions from gel filtration chromatography. M, protein marker. 
NR, under non-reduced condition. Fractions 22-26 were combined for crystallization.  
A 
22 
26 
27 
32
KD
94
67
43
30
20
14
M     22-26   27 28 29 30 31 32
NR 
B
mCHL2
 
BMP2
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Initial screening was performed in sitting drops with the kits of Hampton 1 and 2, 
Hampton SaltRx, and Hampton Index (Hampton Research). Two among the 288 
conditions (Figure 3.41, A and B) were found to give crystals. The condition A served as a 
basis for further optimization and the following fine screen crystallization trials at 
different pH, precipitant concentration, and cryoprotectant (Table 3.9): 
 
Table 3.9: Procedure of screening with pH, precipitant concentration, cryoprotectant reagents 
for the crystallization of mCHL2/BMP-2 complex. 
Original 
condition  
 pH of buffer 
screening  
Precipitant concentration 
screening 
cryoprotectant reagents 
screening 
A 
0.1M Tris, pH 
8.5, 25% w/v 
PEG3350 
 
 
B 
0.1M Tris, pH 8.5, 
25% tert-Butanol. 
 
pH 7.5  
pH 8.0 
pH 8.5 
pH 9.0 
20% w/v PEG3350 
25% w/v PEG3350 
30% w/v PEG3350 
5% 
10% 
15% 
20% 
25% 
30% 
glucose 
saccharose 
Glycerin 
 
 
Single crystals could grow under the conditions of 0.1M Tris, 25% w/v PEG3350 with pH 
7.5, pH 8.0, pH 8.5 and pH 9.0. However no crystal grew in the buffers with 20% and 
30% w/v PEG 3350 (precipitant concentration screening) and in the buffers with different 
cryoprotectants. 
Furthermore, the complex of BMP-2 and CHL2-N89Q/N180Q mutant, which exists as an 
unglycosylated protein, was applied to the initial screening in sitting drops with HR2-110 
kit and crystal screen2 HR2-112 kit (98 buffers). However no crystal was found in all 
these conditions. 
 
3.6.2 Crystallization of mCHL2-VWC3/BMP-2 complex  
 
The purified mCHL2-VWC3 was mixed with BMP-2 at a molar ratio of 2.2:1 on ice. The 
mCHL2-VWC3/BMP-2 complex was isolated by size exclusion chromatography on 
Superdex™ 200 column. The fractions (28-33) containing the complex were pooled 
(Figure 3.42). The purified complex was finally concentrated to 8-11 mg/ml and applied 
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for initial screening in sitting drops. 
 
 
Crystals were found in 9 (A-I) conditions from the kits of HR2-110, HR2-112, HR2-144, 
HR2-108, HR2-130(Hampton Research); Wizard™ I and Wizard™ II screen, Cryo I™ 
and Cryo II™ screen (Emerald BioSystems); JCSG crystallization suite (Qiagen); Classic 
1-10 screen (European Molecular Biology Laboratory, Hamburg) in initial screening 
(Figure 3.43): 
 
 
28 
33 
37 
A 
Figure 3.42: A, Chromatographs of the gel filtration on 
Superdex 200 for 2.2:1 mixture of mCHL2-VWC3 and 
BMP-2; B, SDS-PAGE of the fractions from gel 
filtration chromatography. M, protein marker. NR, under 
non-reduced condition Fraction 28-33 were combined 
for crystallization.
BMP-2
 
VWC3
M 28-33 34 35 36 37 28-33
NR 
BKD
94 
67 
43 
30 
20 
14 
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These conditions were served as a basis for optimization and subsequent fine screening 
trials (I, II, III) with pH, precipitant concentration, cryoprotectant reagents as follows 
(Figure 3.44). 
 
 
 
 
 
 
Figure 3.43: Initial screening of crystallization of mCHL2-VWC3/BMP-2 complex. 
Single crystals grow in these conditions below: A, 1.5M Sodium chloride, 10% v/v 
Ethanol;  B, 0.1M MES, pH 6.5, 1.6 M Magnesium sulfate heptahydrate;  C, 1.26M 
Sodium phosphate monobasic monohydrate, 0.14M Potassium phosphate dibasic, pH 6.0; 
D, 0.8M Succinic acid, pH 7.0;  E, 1.1M Ammonium tartrate dibasic, pH 7.0;  F, 35% 
v/v Tacsimate, pH 7.0;  G, 0.1M Sodium chloride, 0.1M BIS-TRIS, pH 6.5, 1.5M 
Ammonium sulfate;  H, 1.0M Ammonium sulfate, 0.1M BIS-TRIS, pH 5.5, 1% w/v 
Polyethylene glycol 3,350;  I, 1.0M Ammonium sulfate, 0.1M HEPES, pH 7.0, 0.5% w/v 
Polyethylene glycol 8,000.  
A B C
D E F
G H I 
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A 
Original condition 
I: pH of buffer 
screening  
II: Precipitant concentration screening III: cryoprotectant 
reagents screening
A: 1.5M Sodium chloride, 10% v/v Ethanol   1.0M, 1.25M, 
1.5M,  2.0M 
NaCl 
B: 0.1M MES, pH 6.5, 1.6 M Magnesium sulfate 
heptahydrate  
 1.2M, 1.6M, 1.8M 
MgSO4 
C: 1.26M Sodium phosphate monobasic 
monohydrate, 0.14M Potassiumphosphate 
dibasic, pH 5.6 
pH 6.0  
pH 5.6 
1.26M / 0.14M 
1 M / 0.4 M 
0.71M / 0.29M 
NaH2PO4 /K2HPO4 
D: 0.8M Succinic acid, pH 7.0   0.6M, 0.8M, 1.0M Succinic acid 
E: 1.1M Ammonium tartrate dibasic, pH 7.0   0.8M, 
1.1M 
Ammonium 
tartrate dibasic 
F: 35% v/v Tacsimate, pH 7.0   20%, 25%, 30%, 
40%, 45% 
Tacsimate 
G: 0.1M Sodium chloride, 0.1M BIS-TRIS, pH 6.5, 
1.5M Ammonium sulfate   
 
  
H: 1.0M Ammonium sulfate, 0.1M BIS-TRIS, pH 
5.5, 1% w/v Polyethyleneglycol 3,350  
 1.0M,  
1.5M 
(NH4)2SO4 
I: 1.0M Ammonium sulfate, 0.1M HEPES, pH 
7.0, 0.5% w/v Polyethylene glycol 8,000  
pH 7.0  
pH 6.0 
0.8M, 1.0M, 1.2M 
(NH4)2SO4 
 
 
 
5% 
10% 
15% 
20% 
25% 
30% 
Glycerin
 
    glucose 
 
  saccharose
 
B 
A  1M NaH2PO4，0.4M K2HPO4, pH6.0, 25% Glycerin 
B  35% tacsimate, 15% glucose 
C 1.0 M (NH4)2SO4, 0.1 M HEPES pH 7.0, 20% Glucose 
D  1.5M NaCl, 10% ethanol, 25% Saccharose 
C 
A  1M NaH2PO4，0.4M K2HPO4, pH6.0, 25% Glycerin 
 
 
 
 
 
Figure 3.44: Procedure of screening with pH, precipitant concentration, cryoprotectant reagents and 
additive screening for the crystallization of mCHL2-VWC3/BMP-2 complex. A, 9 original conditions 
(A-I) gained from initial screening, were served as a basis for optimization screening trials I (pH), II 
(precipitant concentration) and III (cryoprotectant reagents). B, 4 optimized conditions (A-D) in 
cryo-condition were obtained from A. C, the selected condition A from B was performed for the 
further additive screening to improve the poor diffraction. However, the best diffraction was 15-20 Ǻ. 
 
Additive screening (72 additives 
from kits of Hampton Research) 
Best diffraction was 15-20 Ǻ 
 110
Finally, large single crystals (50-200nm in the first dimension) grew in 4 conditions under 
cryo-conditions (Figure 3.45). However, these crystals showed only very weak diffraction 
with 15-20Ǻ resolution. In order to improve the poor diffraction, the additive screening 
was performed later with the kits of Addition Screen 1-3 (Hampton Research) in the 
condition A (1M NaH2PO4，0.4M K2HPO4, pH6.0, 25% Glycerin). But the results showed 
no improvement. Further optimization steps for the conditions of crystallization and 
probably the protein constructs has to be done in the future experiments.  
 
 
 
 
 
 
 
 
Figure 3.45: Optimization screening of crystallization of mCHL2-VWC3/BMP-2 complex 
with pH, precipitant concentration, cryoprotectant reagents. Single crystals grow in these 
conditions below: A, 1M NaH2PO4，0.4M K2HPO4, pH6.0, 25% Glycerin;  B, 35% 
tacsimate, 15% glucose;  C, 1.0 M Ammonium sulfate, 0.1 M HEPES pH 7.0, 20% 
Glucose;  D, 1.5M NaCl, 10% ethanol, 25% Saccharose. 
A B
C D
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4 Discussion 
 
VWC-containing proteins act as extracellular modulators in the BMP/TGF-β signaling 
pathway and play important roles in development and diseases. CHL2, a novel BMP 
inhibitor, is a member of VWC-containing proteins and interacts with different BMPs, 
inhibiting their actions in vitro as well as in vivo. CHL2 is expressed preferentially in 
chondrocytes of developing cartilages of hip and knee joints and costochondral junction 
(Nakayama et al., 2004). The up-regulation of CHL2 transcripts specifically in middle 
zone cartilage of adult joints was observed with osteoarthritis patients. The significant 
inhibition of cartilage mineralization by up-regulated CHL2 suggested that in 
osteoarthritis cartilages, CHL2 might delay and/or reduce the degree of chondrocyte 
hypertrophy, thereby amending cartilage degeneration. CHL2 may thus play negative 
roles in the (re)generation and maturation of articular chondrocytes in the hyaline 
cartilage of both developing and degenerated joints (Nakayama et al., 2004).  
Although the functions of CHL2 and other Chordin like proteins are extensively studied, 
the structural basis of the interactions of BMPs and CHL2 or other VWC 
domain-containing proteins are still poorly understood. Improving the knowledge of the 
features characterizing the binding mechanisms of CHL2 and BMP-2 interaction is not 
only of theoretical interest, but is important as well for the development of drugs for the 
treatment of degenerated bone diseases, such as osteoarthritis.  
In order to understand the recognition mechanisms of CHL2 for BMPs and especially the 
characteristics of its VWC domains, we analyzed in detail the binding affinities, the 
binding specificities, the binding epitopes and the binding modes of BMP-2 for mCHL2 
and its VWC domains. The interaction of mCHL2 and Tsg has been established for the 
first time in this study. The isolation and crystallization of the complexes of 
mCHL2/BMP-2 and mCHL2-VWC3/BMP-2 paved the way for solving the crystal 
structures of the complexes. 
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Binding of mCHL2/VWC domains to BMPs 
 
CHL2 was demonstrated to inhibit ALP activity induced by BMP-2/4/6/7 and to prevent 
BMP-4 interaction with its BMPR-IB receptor (Nakayama et al., 2004). However, the 
binding affinity of CHL2 for BMPs has not been reported and which domain of CHL2 is 
involved in binding has not been analysed. In our study, we defined the binding affinities 
of mCHL2 for BMP-2, BMP-7 and GDF-5, which are representatives of three BMP 
subfamilies. Full-length mCHL2 bound to BMP-2 with high affinities, which is similar to 
those of Chordin, CV2 and BMPR-IA for BMPs. Two of the three VWCs of mCHL2, 
VWC1 and VWC3, were found to bind BMP-2, and VWC2 did not. Compared with 
full-length mCHL2, VWC1 and VWC3 bound to BMP-2 with about 100 and 20 times 
lower affinity respectively (Table 3.5). The results indicate that the affinity of mCHL2 for 
BMP-2 results from the cooperative binding of VWC1 and VWC3 domains. This is 
similar to Chordin, for which its VWC1 and VWC3 domain bind BMPs cooperatively, 
but different from CV2 which bind BMPs via its single VWC1 domain (Zhang et al., 
2007). Surprisingly, our mutational analysis showed that VWC1 and VWC3 domain of 
mCHL2 bind to knuckle and wrist epitopes, respectively. This differs from the VWC 
domains of Chordin and CV2 which bind mainly to knuckle epitopes of BMP-2. 
Furthermore, even for the knuckle epitope-binding VWC domains, the binding 
determinants are different. These results suggest that the VWC domains exhibit different 
binding characteristics.  
Consistent with the results of the mutational analysis, we found that mCHL2 inhibits the 
binding of BMP-2 to both the type I and type II receptors in vitro, and the single VWC1 
or VWC3 domain can only inhibit the binding of BMP-2 to the type II or type I receptor 
respectively. Interestingly, the individual VWC domain is not able to inhibit BMP 
signaling in cell culture, which indicates that for inhibition of BMP signaling, the 
high-affinity binding of full-length mCHL2 containing both VWC1 and VWC3 domain is 
necessary. It is as yet unknown whether the full-length mCHL2 is proteolytically cleaved 
in vivo. Otherwise, the processing of the mCHL2 molecule would lead to decrease of its 
inhibitory potency as seen for Chordin protein (De Robertis and Kuroda, 2004).  
 113
 
Binding mode of mCHL2/BMP-2 interaction 
 
Our results showed that the affinity of solute mCHL2 to immobilized BMP-2 was about 
10-fold lower than that of solute BMP-2 to immobilized mCHL2. This difference could 
be explained by the assumption that the solute BMP-2 dimer binds simultaneously to two 
immobilized mCHL2 on the chip (1:2 interaction, Figure 4.1, A), which results in an 
enhanced affinity; and the separate mCHL2 binds immobilized BMP-2 in an 1:1 
interaction, which results in a lower affinity (Figure 4.1, B). The similar situation has 
been reported for the BMP/receptor interaction in BIAcore measurement (Greenwald et 
al., 2003; Sebald et al., 2004). Furthermore, our mutational analysis has clearly 
demonstrated that mCHL2-VWC1 and VWC3 bound respectively to the knuckle and 
wrist epitopes of BMP-2. As two wrist and two knuckle epitopes exist in a BMP-2 dimer 
(Figure 4.2, C), it seems that mCHL2 binds BMP-2 dimer in a 2:1 interaction. Finally, the 
stoichiometry of mCHL2/BMP-2 interaction has been determined to be 2:1 by gel 
filtration chromatography (Figure 3.34); Tsg has been shown to bind mCHL2 via the 
cooperative binding of VWC1 and VWC3, and a Tsg/mCHL2/BMP-2 ternary complex 
could be isolated. Based on these results, we suggest a model for mCHL2/Tsg/BMP-2 
interaction in Figure 4.2, A. However, the second possibility in Figure 4.2, B could not be 
excluded from our results. Notably, the binding mode of mCHL2/Tsg/BMP-2 interaction 
is different from those of BMP-2 interacting with the other Chordin family member CV2 
and Chordin (Figure 4.3)(Zhang et al., 2007). CV2 binds BMP-2 also with 2:1 
stoichiometry, but only one VWC domain participates in binding and Tsg is not involved 
in the interaction. In contrast, Chordin binds BMP-2 with an 1:1 stoichiometry, however, 
similar to mCHL2/BMP-2 interaction, two VWC domains and Tsg are involved in this 
binding. In summary, Chordin-like proteins modulate BMP signaling through different 
recognition mechanisms. 
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Figure 4.2: Model of binding mode of mCHL2/BMP-2/Tsg interaction. A, two mCHL2 monomers 
surround the BMP-2 dimer. The VWC1 and VWC3 domain of each mCHL2 monomer respectively -  
Figure 4.1: Scheme illustrates the 2:1 and 1:1 interaction of CHL2 and BMP-2. A, The 
immobilized CHL2 bind to BMP-2 dimer by 2:1 interaction.  B, The CHL2 in solution 
binds to immobilized BMP-2 by 1:1 interaction. The second CHL2 in solution is omitted 
to emphasis the 1:1 interaction. 
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CHL-2 
BMP-2 
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- shares the knuckle epitopes and wrist epitopes of the BMP-2 monomers. Two Tsg bind mCHL2 via 
the cooperative binding of VWC1 and VWC3 of the different mCHL2 monomers and synchronously 
share the wrist epitopes of the BMP-2 monomers. B, VWC domains of CHL2 and Tsg bind to BMP-2 
wrist and knuckle epitopes in the same way in model A, but each CHL2 monomer binds to one side of 
the butterfly shaped BMP-2.  C, BMP-2 signaling complex with type I and type II receptors. 
 
 
 
 
 
Interaction of Tsg and BMP-2/CHL2 
 
Tsg plays important roles in Chordin regulation of BMP signaling. Previous study showed 
that Tsg has Chordin-independent activity which was speculated to be due to other 
Chordin-like proteins (Oelgeschlager et al., 2003). In this study we have established for 
the first time the novel interaction between mCHL2, Tsg and BMP-2. Tsg binds to VWC1 
and VWC3 of mCHL2 and thereby strengthens the binding affinity. A study (Nakayama et 
al., 2004) showed that CHL2 inhibited BMP functions in vitro and in vivo. Our result 
indicates that this inhibition must be enhanced by the presence of Tsg. Recent results from 
Tsg-deficient mice indicated a critical role of Tsg in skeletal development of vertebrates 
(Gazzerro et al., 2006; Nosaka et al., 2003). Tsg has also been shown to be an important 
modulator of BMP-regulated cartilage development and chondrocyte differentiation 
(Schmidl et al., 2006). However, whether Tsg exerts its regulating function in cartilage 
Figure 4.3: A, Model of BMP2/Chordin/Tsg ternary complex. One Chordin monomer binds the 
BMP-2 dimer. The VWC1 and VWC3 domains of Chordin monomer bind respectively the knuckle 
epitopes of the BMP-2 monomers. Two Tsg bind chordin via VWC1 and VWC3 of the chordin 
monomer and synchronously share the wrist epitopes of the BMP-2 monomers. B, Model of
BMP-2/CV2 complex. Two CV2 monomers bind to each side of the BMP-2 dimer via the binding 
of two VWC1 domains to the knuckle epitopes of the different BMP-2 monomer. The cyan box in 
(B) indicates the C-terminal domain of CV2 (Zhang et al., 2007) 
A                                       B
BMP-2 BMP-2 
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through the interaction with Chordin remains questionable, because Chordin is absent 
from all fetal bovine growth plate chondrocyte populations except for resting 
chondrocytes (Schmidl et al., 2006). In situ hybridization studies of the developing mouse 
skeleton showed the absence of Chordin from cartilage proper (Scott et al., 2000; Zhang 
et al., 2002). Thus, at least in the regulation of BMP activity by Tsg in cartilage, other 
modulator proteins might be at work. CHL2 could be one of these proteins, since CHL2 is 
co-expressed with Tsg in cartilage (Nakayama et al., 2004; Schmidl et al., 2006) and they 
bind each other with high affinity. Further studies will have to show the in vivo relevance 
of the Tsg/CHL2 interaction and whether it leads to a pro- or anti-BMP activity. It seems 
unlikely that mCHL2 is cleaved by Xolloid protease like Chordin, since no Xolloid 
cleavage site is found in the mCHL2 sequence. This could mean an important difference 
between the BMP-2/Tsg/Chordin and BMP-2/Tsg/mCHL2 complexes. It remains to be 
seen whether mCHL2 could be cleaved by other proteases. Otherwise, the formation of a 
BMP/CHL2/Tsg complex would only result in a strong anti-BMP activity differing from 
the formation of the BMP/Chordin/Tsg complex, which plays a role as transporter and 
thereby promotes BMP activity in this context (De Robertis and Kuroda, 2004; Eldar et 
al., 2002; Shimmi et al., 2005). 
 
VWC domain is a versatile binding module 
 
VWC-containing proteins play an important role in regulating BMP activity. In contrast to 
the extensive studies on the function of these proteins in development and diseases, the 
structural basis for the mechanisms of BMP regulation by these proteins is still poorly 
understood. The present results and data in the recent literature (Zhang et al., 2007) 
indicate that the VWC domains are versatile binding modules which can exhibit multiple 
binding characteristics as follows:  
1) VWC domains show different affinities and specificities to different BMPs. 
Promiscuities exist in the interaction between different VWC domains and BMPs.  
2) Many VWC domains bind mainly to knuckle epitope of BMP-2 (such as 
Chordin-VWC1/-VWC3, CV2-VWC1 (Zhang et al., 2007) and CHL2-VWC1), but 
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mCHL2-VWC3 
mCHL2-VWC1 
mCHD-VWC1 
mCHD-VWC3 
hColIIA-VWC 
zCV2-VWC1 
 
↓ 1       ↓10          ↓20         ↓30       ↓40                ↓50         ↓60        ↓70  
                        * * *    * 
LKEKHKKACTHNG..KTYSHGEVWH.PTV.LSFGPMPCILCTCID..........GYQDCHRVT..CPTQYP.CSQPKK.VAGKCCKICPE 
ARSRSGKVCLFGE..KIYTPGQSWH.PYL.EPQGTIYCVRCTCSE.........NGHVNCYRLR..CPPLH..CSQPV.MEPQQCCPRCVD 
LPVRGAAGCSFGG..KVYALDETWH.PDLGEPFGVMRCVLCACEAPQWARRGRGPGRVSCKNIKPQCPTLA..CRQPRQ.LPGHCCQTCPQ 
PNLEPGEGCYFDGDRSWRAAGTRWH.PVV.PPFGLIKCAVCTCKG........ATGEVHCEKVQ..CPRLA..CAQPVRANPTDCCKQCPV 
QDVQEAGSCVQDG..QRYNDKDVWK.PEP........CRICVCDT..........GTVLCDDII..CEDVKD.CLSP.EIPFGECCPICPT 
LITGTEASCENEG........EVLHIPNITDNP....CISCVCLN..........QKAECKQEK..CAPLAEDCALVVK.QTGACCEKCKG 
  ** *  *                 *  *         *                  * 
|－  Clip－|－－－－－  －  －  －  －  －  －  －  －－  － － SD1－  －  －  －  －  －  －  －  －  －  － －  －  －  －  －  －  －  － －－ －  －| －  －  －  － －－ －      SD2 －－－ －  －  －  － －  － | 
 
Figure 4.4: Sequence alignment of VWC domains. VWC domains from different chordin family proteins 
were aligned by Multalin. mCHL2: murine Chordin like 2; mCHD: murine Chordin; hColIIA: human 
collagen IIA; zCV2: zebra fish Crossveinless-2. Residues are coloured according to conservation 
(hydrophobic: green; cysteine: yellow; positive charged: red; negative charged: purple; uncharged 
hydrophilic: blue. *, the determinants of mCHL2-VWC3 and CV2-VWC1. Clip, a short N-terminal 
segment of zCV2-VWC1. SD1 and SD2, sub-domain 1 and 2 of zCV2-VWC1 (Modification from zhang 
et al., 2008). 
CHL2-VWC3 for instance, binds preferentially to the wrist epitope of BMP-2. 
Moreover even for the same epitope of BMP-2, different determinants are found for 
different VWCs. 
3) VWC domain binds not only BMPs but also Tsg. Interestingly, only the BMP-binding 
VWC domains bind Tsg, indicating cooperation of these two binding proteins. 
Furthermore, the binding of individual VWC domain to Tsg could be independent (e.g. 
VWC1 and VWC3 of Chordin) or cooperative (e.g. VWC1 and VWC3 of mCHL2).  
4) VWC domain plays not only a functional role such as BMP/Tsg binding, but also a 
purely structural role as many non-binding VWCs only function to space the different 
parts of the full-length proteins of the Chordin family. 
 
Binding determinants of mCHL2-VWC3 for BMP-2 
The NMR structure of the ColIIA VWC domain established for the first time a two 
sub-domains (SD) architecture of the VWC domain (O'Leary et al., 2004). The idea that 
corresponding sub-domains SD1 and SD2 are present in all VWC domains is further 
substantiated by the recently solved crystal structure of BMP-2/CV2-VWC1 complex 
(Zhang et al., 2008). Furthermore, the crystal structure revealed that the N-terminal 
extension before the first cysteine termed clip and the SD1 of CV2-VWC1 encode high 
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affinity binding for BMP-2. The clip of CV2-VWC1 is not conserved in many other 
VWC domains including VWC1 and VWC3 of mCHL2 (figure 4.4). However, the four 
mCHL2-VWC3 determinants for BMP-2 binding found in this study are located in a 
region corresponding to the long-loop between β-strands 1 and 2 of CV2-VWC1 (Figure 
4.4). As the residues in this loop of CV2-VWC1 contribute strongly to the hydrophobic 
interaction with BMP-2, it is tempting to speculate that this loop might be also important 
for the binding of other VWC domains to BMPs. It should be noted that in contrast to 
CV2-VWC1, the mCHL2-VWC3 domain binds only to the wrist epitope of BMP-2. 
Further studies have to establish the architecture of the binding epitopes of 
mCHL2-VWC3 and whether residues in different parts of the domain can be involved in 
BMP binding. In addition, as the mCHL2-VWC3 also binds the wrist epitope-binding 
protein Tsg, it will be interesting to discuss how the mCHL2-VWC3 epitope for Tsg is 
construced and whether this epitope is overlapping with or different from that for BMP 
binding. 
 
Crystallization of CHL2/BMP-2 and CHL2-VWC3/BMP-2 complex 
 
Crystallography is a powerful method to solve the structure of a protein or a protein 
complex. The crystal structure of the complexes of CHL2/BMP2 and 
CHL2-VWC3/BMP2 will reveal the protein-protein recognition in atomic details. We 
have successfully isolated CHL2/BMP-2 and CHL2-VWC3/BMP-2 complexes in 
reasonable amounts and these complexes are stable in concentration up to 10 mg/ml 
(Figure 3.40; 3.42). Further experiments have shown that these complexes can be 
crystallized under many conditions. We have established a sound basis for the possible 
crystallization of these complexes. The subsequent experiments are under way.  
Why do the macroscopically well formed crystals show poor diffraction? There are some 
possible reasons. One of the main reasons is that the proteins have a high degree of 
structural flexibility. Therefore protein structural heterogeneity and disorder existing in 
solution may also exist in the crystalline form, due to freedom afforded by the high 
solvent content in most protein crystals (DePristo et al., 2004; Smith et al., 1986). Thus, 
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the screening of ligands, additive, co-factors, temperature, or protein concentrations may 
reduce or eliminate improper folding of protein and help the target protein to assume a 
more rigid and homogeneous conformation and thereby improve the diffraction (Hassell 
et al., 2007). The other reason for the poor diffraction of crystal is structural variations in 
the protein due to partial deamination, partial oxidation and other post-translational 
modifications during protein expression or protein purification and even the process of 
crystallization. Therefore, the optimization of purification methods between proteins 
expression and crystallization may avoid the possible structural modifications in the 
protein and improve the diffraction of crystal (Hampton Research. 
http://www.hamptonresearch.com). Furthermore, the high rate of crystal growth may 
indicate a high level in the number of defects in the crystal lattice. Thus, slowing the rate 
of crystal growth might help improving the diffraction of the crystal (Yoshizaki et al., 
2001). Finally, cryo-method (Juers et al., 2007; Juers and Matthews, 2004) and additive 
application can affect the diffraction of crystal. We have tested different optimization 
methods to improve the diffraction pattern of the crystal of mCHL2-VWC3/BMP-2 
complex. These methods include pH, precipitant concentration, cryprotectant and additive 
screenings. Currently no good condition has been found. Thus, further optimizing steps 
for crystallization condition or protein constructs are necessary to obtain well diffracting 
crystals. 
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5. Summary 
 
The proteins containing Von Willebrandt factor type C (VWC) domains act as 
extracellular modulators in the BMP/TGF-β signaling pathway. Though the functions of 
VWC-containing proteins in development and diseases have been studied extensively, the 
structural basis of BMP/VWC-containing protein interaction is still poorly understood. In 
this thesis, mouse Chordin-like 2 (mCHL2), a novel Chordin-like protein which is a 
member of the VWC-containing proteins was selected to study the structural basis of 
BMP-2/VWC protein interaction. The binding affinities, the binding specificities, the 
binding epitopes and the binding modes of BMP-2 for mCHL2 and its VWC domains 
were analyzed. Tsg has been established as a novel binding partner of mCHL2. The 
isolation and crystallization of the complexes of mCHL2/BMP-2 and 
mCHL2-VWC3/BMP-2 paved the way for solving the crystal structures of the complexes. 
According to our results, we can make the following conclusions. 
 
Full-length mCHL2 binds to BMP-2 with high affinities. Two of the three VWCs of 
mCHL2, VWC1 and VWC3, bind to BMPs, and VWC2 does not. The affinity of mCHL2 
for BMP-2 is the result of the cooperative binding of VWC1 and VWC3 domains.  
 
mCHL2 can inhibit the binding of BMP-2 to both type I and type II receptors. With 
regard to VWC1/VWC3, the mCHL2-VWC1 can only inhibit the BMP-2/type II 
receptors binding and mCHL2-VWC3 only inhibit the binding of BMP-2 to type I 
receptors. 
 
Mutational analysis for VWC3 showed that four of the seven mutants VWC3-H237D, 
VWC3-P238R, VWC3-V240D, and VWC3-G244A exhibited decreased binding affinities 
for BMP-2 compared to wild type VWC3, indicating that these four amino acids are 
binding determinants for BMP-2. These residues are located in a region corresponding to 
the long loop of CV2-VWC1 which has previously been shown to be important for 
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BMP-2 binding of CV2-VWC1. This probably indicates that similar to CV2-VWC1, the 
N-terminal part of mCHL2-VWC3 is responsible for BMP-2 binding, even if in contrast 
to CV2-VWC1, mCHL2-VWC3 binds only to the wrist epitope of BMP-2. 
 
Biacore and chromatographic methods prove that mCHL2 binds to BMP-2 with a 
stoichiometry of 2:1, which is an important guide for the further isolation of the 
mCHL2/BMP-2 complex. The stable complexes of mCHL2/BMP2 and 
mCHL2-VWC3/BMP2 have been successfully isolated for crystallization experiments. 
Though the crystals obtained can’t be analyzed because of their low diffraction, these 
results suggest that well diffracting crystals can be obtained in the future. 
 
We have established the novel interaction between mCHL2, Tsg and BMP-2 for the first 
time. Tsg binds to VWC1 and VWC3 of mCHL2 in a cooperative way and plays a role in 
strengthening the binding affinity. Furthermore, Tsg/mCHL2/BMP-2 ternary complex and 
Tsg/mCHL2 binary complex have been isolated by gel-filtration chromatography. 
Therefore mCHL2 can form a ternary complex with Tsg and BMP-2 and this complex 
makes mCHL2 a better BMP-2 antagonist.  
 
The work presented in this thesis improves understanding the regulatory mechanisms of 
BMPs/VWC-containing proteins. Further crystallization analysis of mCHL2 or its VWCs 
and BMP-2 complex is needed to reveale in detail the molecular basis of 
BMPs/VWC-containing proteins interaction. 
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